Search

Your search keyword '"L G Zhukova"' showing total 32 results
Start Over Author "L G Zhukova" Topic medicine.medical_specialty
32 results on '"L G Zhukova"'

1. Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice

Author

Inna P. Ganshina, Elena G. Ovchinnikova, Oksana M. Shalaeva, Svetlana V. Kuzmicheva, Alina N. Fedorova, Asiat I. Tekeeva, Alexander V. Sultanbaev, Elena V. Markizova, L G Zhukova, Ksenia S. Maistrenko, Svetlana A. Orlova, Irina V. Evstigneeva, Daniil L'vovich Stroyakovskiy, James J. Kolokolov, Olesya A. Kuchevskaya, Oksana N. Shirokova, Oksana I. Arapova, Elena V. Zueva, Anna V. Vasilevskaya, Tatyana A. Nersesova, Arshak A. Akopyan, Irina V. Kolyadina, Larisa Bolotina, Mariam Z. Yakubova, Sergey P. Medvedev, Alexandr S. Dergunov, Irina A. Shangina, Elvira A. Bobrova, Chulpan K. Valiakhmetova, Anna E. Storozhakova, Aleksei V. Emshanov, Natalia V. Fadeeva, Mikhail V. Volkonskiy, Yulia I. Merzlikina, Galina V. Antonova, Ivan A. Luev, Alisa R. Shumskikh, Natalia Yu. Samaneva, Elena Karabina, Natalia R. Abidova, Viktoria S. Egurenkova, Vasily V. Marfutov, Irina E. Gudkova, Lyubov Vladimirova, and Olesya A. Stativko

Subjects
Oncology, Cancer Research, medicine.medical_specialty, combined endocrine therapy with cdk4/6 inhibitors, cdk4/6, medicine.medical_treatment, Subgroup analysis, Metastasis, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, visceral metastases, Internal medicine, eribulin chemotherapy efficacy, Medicine, Adverse effect, eribulin, RC254-282, Chemotherapy, business.industry, hr+/her2- metastatic breast cancer, Cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lung metastases, medicine.disease, Metastatic breast cancer, Regimen, chemistry, eribulin chemotherapy safety, 030220 oncology & carcinogenesis, business, hormone resistance, 030215 immunology, Eribulin
Abstract

Relevance. Data on the efficacy of endocrine and chemotherapy regimens in patients with hormone-resistant metastatic breast cancer (mBC) after progression with CDK4/6 inhibitors are limited; the search for an effective therapy regimen in this clinical situation is an urgent task of clinical oncology. Aim. Evaluate the efficacy and safety of eribulin therapy in patients with HR+/HER2- mBC after progression with CDK4/6 inhibitors; compare the results of the Russian study and the EMPOWER observational study in the USA. Materials and methods. The Russian observational study included 54 patients (pts) with HR+/HER2- mBC, who were treated with eribulin after CDK4/6 inhibitors in 24 Russian Cancer hospitals. The median age of pts was 56 years; 75.9% of them had recurrent BC, 24.1% de novo BC stage IV; 51.9% of pts had progression with CDK4/6 inhibitors in the first 6 months of therapy (primary endocrine resistance); 48.1% of patients had progression in the period from 6 to 38 months; 89.1% had visceral site of metastases (liver MTS 65.5%, lung MTS 52.8%, brain MTS in 7.5%). Eribulin was used after anthracyclines and taxanes in 94.4% of cases. The efficacy and safety of eribulin therapy in patients with HR+/HER2- mBC after progression with CDK4/6 inhibitors was studied, as well as subgroup analysis according to age, sites of metastasis, and previously treatment options. Results. Eribulin was prescribed in the standard regimen of 1.4 mg/m2 on days 1 and 8, the interval between cycles was 21 days, the number cyclys of chemotherapy was 144 (median 8, the mean number of cycles 10.5). With a median follow-up of 11.5 months (from 3 to 36 months), 30 patients (55.6%) continue therapy with eribulin at present; therapy was cancelled in 24 patients due to progression in 22 (40.7%) cases, and due to intolerable toxicity in 2 (3.7%) patients. The maximum response to eribulin therapy included partial response (in 11 cases, 24.4%), stable disease (in 30 cases, 66.7%) and progression in 4 (8.9%) patients. Median PFS with eribulin therapy was 10.0 months; the 6-month, 1-year, and 2-year PFS were 79.5%, 44.8% and 26.5%, respectively. Eribulin therapy was equally effective in different subgroups (p0.05) and did not depend on the age of patients, the previously received treatment, the presence of visceral MTS and liver damage. The best response to chemotherapy with eribulin was observed in lung metastases: median PFS 24 months vs 9.1 months, p=0.056. The safety profile was favorable; adverse events were registered in 34.5% of patients, which required dose adjustment in 18.5% of cases. With a median follow-up of 11.5 months, 92.6% of patients remain alive. Conclusion. Eribulin has demonstrated high efficacy and favorable safety profile in hormone-resistant HER2- mBC in patients with progression when receiving CDK4/6 inhibitor.

Published
2021

2. Abstract PS10-05: Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial

Author

J. Wu, Constanta Timcheva, L. Menon-Singh, Miguel Martín, Katie Zhou, Guy Jerusalem, Michelino De Laurentiis, Claudio Zamagni, L G Zhukova, Janice Lu, Aleix Prat, Senthil Rajappa, Paul Cottu, and Stephen Chia

Subjects
Cancer Research, medicine.medical_specialty, education.field_of_study, business.industry, Letrozole, Population, Goserelin, Neutropenia, medicine.disease, Gastroenterology, Discontinuation, Breast cancer, Oncology, Tolerability, Internal medicine, medicine, business, education, Progressive disease, medicine.drug
Abstract

Background: CompLEEment-1 (NCT02941926) is an ongoing Phase IIIb trial of ribociclib (RIB) in combination with letrozole (LET) in the first-line setting for patients (pts) with HR+, HER2- ABC, reflecting a real-world clinical setting by including a more diverse pt population than those included in the pivotal MONALEESA trials. Here we report further analyses of the primary endpoint of safety from the completed Core Phase of the trial. Methods: CompLEEment-1 included women of any menopausal status and men with HR+, HER2- ABC treated with ≤1 line of prior chemotherapy and no prior hormonal therapy for advanced disease. Pts received RIB (600 mg QD, 3 weeks on/1 week off) in combination with LET (2.5 mg QD, continuous). Premenopausal women and men received a luteinizing hormone-releasing hormone agonist (3.6 mg goserelin or 7.5 mg leuprolide, Q28D). The primary endpoints were safety and tolerability. Updated analyses included dose reduction/interruption or treatment discontinuation due to adverse events (AEs), clinical impact of AEs of special interest (AESI), and exposure-adjusted incidence/occurrence rates (IRs) for AESI. Results: At data cutoff (November 8, 2019) 3,246 pts had been evaluated (median follow-up of 25.4 months), and median duration of exposure to RIB was 17.5 months; 1,301 (40.1%) pts completed Core Phase treatment, 415 of whom moved to the Extension Phase. Overall, 1,945 (59.9%) pts permanently discontinued treatment, mostly due to progressive disease (34.2%) and AEs (15.5%). Treatment-related AEs were reported in 3,091 (95.2%) pts, leading to dose modification in 2,235 (68.9%) pts. Dose modification occurred most often in pts with grade ≥3 neutropenia (dose interruption, 1,671 [51.5%] pts; dose reduction, 480 [14.8%] pts); treatment discontinuation occurred most frequently in pts with grade ≥3 increased alanine aminotransferase (ALT; 116 [3.6%] pts) or aspartate aminotransferase (AST; 68 [2.1%] pts). Grade ≥3 neutropenia occurred in 1,856 (57.2%) pts, with the median time to first occurrence of 4.1 weeks and median duration of first occurrence of 1.1 weeks. As measured by laboratory values, grade ≥2 increased ALT and AST occurred in 453 (14.0%) and 380 (11.7%) pts, respectively. Grade ≥2 QTcF prolongation was infrequent, occurring in 101 (3.1%) pts, leading 8 (0.2%) pts to discontinue from treatment. AESI rarely led to hospitalization (0 to 0.3%) and none were fatal. Exposure-adjusted IRs for AESI per 100 patient-years of exposure show that with increasing RIB exposure, the IR and the event rates for AESI decreased by a factor of ×2 to ×8 from 0-1 years compared with 1-2 years (Table 1). Conclusions: AEs associated with RIB + LET combination therapy were manageable, consistent with previous Phase III trials of RIB + LET - and adjusted IRs for AESI notably decreased from Year 1 to Year 2 of treatment. These data further support the use of RIB + LET for first-line treatment of HR+, HER2- ABC in both men and women of any menopausal status and in a broader and more diverse patient population. Table 1. Exposure-adjusted IRs for selected AESI per 100 patient-years of exposure0-1 years1-2 yearsAESIIR per 100 PTYaEvents per 100 PTYbIR per 100 PTYaEvents per 100 PTYbNeutropenia276.76410.2292.43200.83ALT increased20.3741.663.796.32AST increased17.5133.272.944.61QTcF prolongation8.4410.221.081.26aIR per 100 PTY: n/100 PTY, number of patients with an event divided by the corresponding sum of the exposure duration for patients, where duration of exposure in patient treatment-years (PTY) is counted up to the first qualifying event (or duration of exposure in time interval for patients without an event).bEvents per 100 PTY: n/100 PTY, number of events divided by the corresponding sum of the exposure duration, where duration of exposure in patient treatment-years (PTY) is duration of exposure in time interval. Citation Format: Janice Lu, Paul Cottu, Miguel Martín, Claudio Zamagni, Aleix Prat, Stephen Chia, Guy Jerusalem, Senthil Rajappa, Constanta Timcheva, Lyudmila Zhukova, Katie Zhou, Jiwen Wu, Lakshmi Menon-Singh, Michelino De Laurentiis. Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS10-05.

Published
2021

3. Renal service during the COVID-19 pandemic (Association of nephrologists position statement)

Author

L. G. Zhukova, Irina Bobkova, А. B. Zulkarnaev, D. V. Politov, Vladimir Dobronravov, V. N. Stepanov, S Sh Butrimova, E. V. Tkachenko, Alexei Smirnov, A. A. Shumilina, E. V. Antonova, M. V. Bush, A. V. Vatazin, and M. M. Batiushin

Subjects
Position statement, Nephrology, Service (business), medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, Context (language use), Quality of life (healthcare), Internal medicine, Health care, Emergency medicine, Pandemic, Medicine, business
Abstract

The editorial touches upon the problem of the possible impact of COVID-19 on CKD patients, mediated by the forced reorganization of the health care system in a whole, the redistribution of its resources in the context of the COVID-19 pandemic. Lack of regular outpatient monitoring, delayed diagnosis and therapy in patients with kidney dysfunction are factors of adverse clinical outcomes - accelerated disease progression, ESKD development and the need for KRT, life-threatening complications, reduced quality of life and survival. The data of a pooled analysis of the impact of the pandemic on specialized renal care and its availability in a number of regions of the Northwest Federal District of Russia and the Moscow Region are presented: a fall in hospital admissions, outpatient consultations and a decrease in the use of hospital beds (on average, by 37 %, 40 % and 32 %, respectively). Principles and conditions of the functioning of health systems associated in the COVID-19 pandemic have been discussed. The main approaches to maintaining the standard level of renal patients care have been formulated, aimed at preventing an unfavorable patient-oriented CKD outcomes. © 2021 Patristica et Mediaevalia. All rights reserved.

Published
2021

4. Olaparib in the metastatic HER2-negative breast cancer setting

Author

E. V. Lubennikova, L G Zhukova, E. I. Khatkova, Inna P. Ganshina, and Irina V. Kolyadina

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, parp-inhibitor, lucy, olaparib, Olaparib, 03 medical and health sciences, chemistry.chemical_compound, breast cancer, 0302 clinical medicine, Breast cancer, Internal medicine, medicine, business.industry, HER2 negative, General Medicine, medicine.disease, 030104 developmental biology, chemistry, olympiad, 030220 oncology & carcinogenesis, brca, Medicine, business
Abstract

Understanding of cancer biology is at the cornerstone of design of new and effective treatment strategies. Identification of molecular drivers of tumor growth and progression allow identify right patient for the right treatment for personalized treatment plan optimization. Breast cancer (BC) encompasses a heterogeneous collection of neoplasms with diverse morphologies, molecular phenotypes, responses to therapy, probabilities of relapse and overall survival. Molecular and histopathological classification aims to categories tumors into subgroups to inform clinical decisions, to improve long-term treatment results and maintain the quality of life of this group of patients. Germinal mutation in the BRCA1/2 (BRCAm) genes in a tumor determines the hereditary predisposition, disease manifestation, therapeutic options and clinical efficacy. Therefore, patients withBRCAmBCrepresent a special subgroup requiring personalized treatment approach.Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, is a targeted therapeutic agent that acts as inhibitor of single-strand breaks reparation, leading to their accumulation, conversion to double-strand breaks and eventually to cancer cell apoptosis. Olaparib is a first-in-class PARP-inhibitor with an outstanding antineoplastic activity known for some malignant tumors, demonstrates effectiveness and safety of therapy inBRCAmBCas well. The results of OlympiAD and LUCY trials are represented in the article. Subgroup analysis may define the patient population that would benefit from PARP inhibitors therapy.

Published
2020

5. Efficacy and safety of cisplatin and paclitaxel (PlaTax regimen) in the neoadjuvant treatment of patients with stage II–III triple-negative breast cancer

Author

O. O. Gordeeva, I. V. Kolyadina, L. G. Zhukova, I. P. Ganshina, G. V. Vyshinskaya, M. A. Kazantseva, M. V. Sukhova, O. E. Ryabishina, E. V. Lubennikova, D. A. Filonenko, E. I. Chichikov, I. N. Polushkina, E. I. Borisova, A. N. Lud, and A. A. Meshcheryakov

Subjects
0301 basic medicine, medicine.medical_specialty, Neutropenia, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, pcr, Internal medicine, medicine, Pharmacology (medical), Radiology, Nuclear Medicine and imaging, Stage (cooking), Adverse effect, Triple-negative breast cancer, business.industry, predictors of pcr, Obstetrics and Gynecology, prognostic factors, Gynecology and obstetrics, medicine.disease, Regimen, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, triple negative breast cancer, Toxicity, Cohort, RG1-991, Surgery, business, Polyneuropathy, neoadjuvant chemotherapy
Abstract

Background. Treatment results for the patients with stage II–III triple negative breast cancer (TN BC) have to be improved. Not only the new treatment regimens, but new predictive and prognostic factors should to be developed.Materials and methods. We included 98 patients with stage II–III TN BC in our study. We studied efficacy and safety of PlaTax regimen (cisplatin 75 mg / m2 day 1 + paclitaxel 80 mg / m2 days 1, 8, 15, course every 4 weeks) in this cohort of patients. We assessed pathologic response, survival and factors, which were relevant for predicting response and prognose survival.Results. PlaTax regimen is characterized by high efficacy and tolerable toxicity. Clinical efficacy was 85.8 %, pCR achievement was 60.5 %, tpCR achievement was 58.1 %. The regimen has low haematological toxicity (neutropenia III–IV grades – 4.1 %); the most frequent adverse events were polyneuropathy (18.5 %) and decreased renal function (24.5 %). 3-year progression-free survival was 68.4 %, most of the relapses (92 %) occurred during first 2 years. 3 year overall survival was 77.6 %. The most relevant predictive factor was level of Ki-67 ≥50 % (pCR 38.5 % vs. 68.7 %, p = 0.038). pCR achievement was the most important prognostic factor, resulting in improved 3-year progressionfree survival (44.3 % vs. 89.1 %, p Conclusions. Our data suggest that studied regimen could be an option for patients with stage II–III TN BC. The assessment of the predictive and prognostic factors will help improve the treatment results for patients with stage II–III TN BC.

Published
2020

6. The place of CDK4/6 inhibitors in real clinical practice for patients with hormone-positive HER2-negative advanced breast cancer: opinion of Moscow’s oncologists

Author

L. G. Zhukova and M. A. Mukhina

Subjects
Oncology, medicine.medical_specialty, Combination therapy, Advanced breast, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, medicine, Pharmacology (medical), Radiology, Nuclear Medicine and imaging, 030212 general & internal medicine, Aromatase, biology, Fulvestrant, business.industry, Endocrine therapy, Obstetrics and Gynecology, Cancer, Gynecology and obstetrics, cdk4/6 inhibitors, medicine.disease, Clinical Practice, 030220 oncology & carcinogenesis, RG1-991, biology.protein, Surgery, hormone-positive her2-negative advanced breast cancer, business, medicine.drug
Abstract

The use of CDK4/6 inhibitors in combination with endocrine therapy (aromatase inhibitors and fulvestrant) allowed us to radically change our understanding of opportunities in the treatment of hormone-positive HER2-negative advanced breast cancer and determine optimal therapy sequencing. The results of randomized clinical trials and over 5-years accumulated international experience in the use of CDK4/6 inhibitors in real clinical practice prove that the use of combinations with CDK4/6 inhibitors can achieve significant efficacy results and increase the survival rates when prescribed in 1 and 2 lines of treatment.In this paper, we present the results of a survey conducted in July–October 2019 among 48 oncologists in Moscow, that were asked to choose, in their opinion, the most preferable patient’s profile and molecular and biological features of hormone-positive HER2-negative advanced breast cancer, in which the use of combination therapy with CDK4/6 inhibitors will provide the greatest benefit.Conflict of interest. MD M.A. Mukhina is the medical director of oncology in the Eurasia and Baltic region of Pfizer Innovations Company

Published
2020

7. Abstract P2-16-34: Patterns of survival and efficacy of chemotherapy in elderly patients with triple-negative breast cancer treated in the neoadjuvant setting

Author

L G Zhukova, Irina V. Kolyadina, Olga O. Gordeeva, Inna P. Ganshina, Andrey Meshcheryakov, and Dmitry Komov

Subjects
Cisplatin, Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Breast surgery, Cancer, medicine.disease, Breast cancer, Internal medicine, medicine, Stage (cooking), business, Neoadjuvant therapy, Triple-negative breast cancer, medicine.drug
Abstract

Background. Triple negative breast cancer (TNBC) is the most aggressive molecular subtype. It is mostly observed in younger patients, however, substantial proportion of patients are above age of 60. Despite that, this group of patients was not studied and analyzed separately in previous studies. Objectives. To establish efficacy of neoadjuvant chemotherapy in elderly patients with stage II-III TNBC and patterns of progression for this group of patients. Methods. Since 2014 we treated 92 patients with histologically confirmed stage II-III TNBC. Neoadjuvant therapy included 6 cycles of Cisplatin 75mg/m2 day 1 and Paclitaxel 80mg/m2 days 1, 8, 15, every 4 weeks according to local protocol. After neoadjuvant chemotherapy patients proceeded to radical breast surgery with assessing pathological response. Then we analyzed clinical characteristics of patients and their survival according to the pathological response achieved. Results. In our analysis were included 92 patients, 22 of them were elderly patients (above 60). Pathological complete response was achieved in 57,6% of all patients. In the elderly group we observed significantly higher proportion of tumors with advanced stages (N3: 40,9% vs 20,0%, p Table 1. Survival outcomes.SurvivalBelow 60 y.o.Above 60 y.o.Recurrence-free survival Conclusion. In our analysis elderly patients with early and locally advanced TNBC demonstrate decreased response, another safety profile and lower survival rates. Different efficacy could be explained with lower number of cycles of neoadjuvant chemotherapy administered and more advanced stages upon presentation. Different metastatic patterns which we observed in younger and elderly patients should be further studied. Citation Format: Olga Gordeeva, Irina Kolyadina, Lyudmila Zhukova, Inna Ganshina, Dmitry Komov, Andrey Meshcheryakov. Patterns of survival and efficacy of chemotherapy in elderly patients with triple-negative breast cancer treated in the neoadjuvant setting [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-16-34.

Published
2020

8. Postneoadjuvant therapy: a new approach to the treatment of HER2-positive breast cancer (KATHERINE study results)

Author

L. G. Zhukova and S. A. Smolin

Subjects
Oncology, medicine.medical_specialty, Tumour regression, medicine.medical_treatment, katherine, chemistry.chemical_compound, Breast cancer, breast cancer, Trastuzumab, Internal medicine, her2-positive breast cancer, medicine, Adjuvant therapy, skin and connective tissue diseases, residual tumor, Neoadjuvant therapy, trastuzumab emtansine, t-dm1, business.industry, adjuvant therapy, General Medicine, medicine.disease, Interim analysis, idfs, chemistry, Trastuzumab emtansine, Medicine, business, Adjuvant, medicine.drug
Abstract

Up until recently, neoadjuvant and adjuvant treatment regimens for breast cancer (BC) were considered equivalent in their effect on long-term treatment outcomes. Despite the fact that additional information on the prognosis of patients (achievement or failure to achieve complete drug pathomorphosis) was obtained during neoadjuvant therapy, we could not change this prognosis, since there was no evidence that any variant of adjuvant therapy could improve survival of patients, who did not achieve complete morphological tumour regression. In December 2018, investigators presented the results of the first planned interim analysis of invasive disease-free survival (iDFS) of patients with early HER2-positive breast cancer, who had residual tumour after neoadjuvant anti-HER2-containing therapy, depending on the adjuvant treatment option: either trastuzumab emtansine (n = 743) or trastuzumab (n = 743). The expected 3-year iDFS in patients, who received trastuzumab emtansine as adjuvant therapy, was 88.3%, while that in the standard trastuzumab group accounted for only 77% (RR = 0.50; 95% CI 0.39–0, 64; h

Published
2019

9. The role of systemic therapy in localized pancreatic cancer (review)

Author

B. I. Bammatov, K. S. Grechukhina, S. A. Smolin, and L. G. Zhukova

Subjects
Resectable Pancreatic Cancer, Oncology, medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Gastroenterology, Cancer, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, medicine.anatomical_structure, Borderline resectable, Surgical oncology, 030220 oncology & carcinogenesis, Pancreatic cancer, Internal medicine, medicine, Adjuvant therapy, Surgery, 030212 general & internal medicine, Pancreas, business, Neoadjuvant therapy
Abstract

The results of treatment of localized (early) pancreatic cancer are unsatisfactory despite all achievements of modern clinical and surgical oncology. Nevertheless, certain success was achieved even in these extremely unfavorable patients regarding their prognosis. The authors analyzed evolution of adjuvant therapy, as well as new concepts in the treatment of borderline resectable and resectable pancreatic cancer. Modern anticancer therapy with acceptable toxicity profile significantly improved the outcomes. However, further research is needed to improve the effectiveness of treatment despite favorable current results.

Published
2019

10. Role of palbociclib in the treatment of hormone receptor-positive HER2-negative metastatic breast cancer. Generalizing results of randomized trials and real clinical practice

Author

L. G. Zhukova, E. I. Khatkova, P. S. Feoklistova, K. S. Grechukhina, S. A. Smolin, E. A. Arutyunyan, and E. M. Kolyago

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, palbociclib, business.industry, General Medicine, Palbociclib, endocrinotherapy, medicine.disease, Clinical Practice, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Breast cancer, breast cancer, 030220 oncology & carcinogenesis, Internal medicine, medicine, Medicine, business, skin and connective tissue diseases, neoplasms
Abstract

Palbociclib is the first-in-class drug of CDK 4/6 inhibitors group. The use of palbociclib in combination with endocrinotherapy (ET) opens up new possibilities for the treatment of metastatic hormone receptor-positive (HRP+) HER2-negative (HER2-) breast cancer (mBC). Palbociclib has gained world attention and is included in all clinical guidelines, both international and domestic, as a new standard of first- and second-line therapy of HRP+ HER2- mBC. The article presents the updated results of PALOMA-2 and PALOMA-3 studies and the results of use of palbociclib in combination with ET in real clinical practice.

Published
2019

11. Assessment of the receptor status in primary breast cancer with synchronous loco regional metastases: prognostic and clinical role?

Author

O. O. Gordeeva, L. G. Zhukova, I. V. Kolyadina, and I. P. Ganshina

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Receptor Status, her2, medicine.medical_treatment, Estrogen receptor, survival, Targeted therapy, Metastasis, sex hormone, 03 medical and health sciences, breast cancer, 0302 clinical medicine, Breast cancer, progesterone receptors, Internal medicine, Progesterone receptor, medicine, metastasis, skin and connective tissue diseases, RC254-282, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, estrogen receptors, medicine.disease, Metastatic breast cancer, Primary tumor, 030104 developmental biology, 030220 oncology & carcinogenesis, business
Abstract

Background. Assessment of hormone receptor status plays a crucial role in treatment of patients with breast cancer. currently, clinicians are limited to determining the expression status of estrogen receptor (ER), progesterone receptor (pR) and HER2 only in primary breast cancer tissues, even in the presence of regional metastases.The purpose of the study was to review available data on heterogeneity of ER, pR and HER2/neu expressions in primary breast cancer and regional metastases.Material and methods. We analyzed publications available from pubmed, medline etc. using the keywords «discordance», «breast cancer», «locally advanced», «regional lymph nodes», «ER», «pR», and «HER2».Results. The clinical and prognostic role in assessing the heterogeneity of the receptor status of primary tumors and synchronous regional metastases, as well as the effect of detected discordance on treatment tactics was assessed.Conclusion. Data on the frequency of discordance in hormone receptor status between primary and metastatic breast cancer tumors and its effect on the further prognosis in breast cancer are still contradictory. However, the fact of the presence of such heterogeneity suggests that some patients with affected lymph nodes will have significant benefits from determining the status of steroid hormones and HER2 not only in the primary tumor, but also in the lymph nodes, since it will open up new opportunities for subsequent targeted therapy.

Published
2019

12. BJS commission on surgery and perioperative care post-COVID-19

Author

E. Abahuje, A. Abbas, M. Abd El Aziz Abd El Maksoud, A. Abdelhady, S. Abdelhamid, H. Abdelkarem Ahmed Faraj, B. Abdelqader, T. Abdelrahman, H. Abdou, A. Abdullah, M. Abedua Harrison, E. Abem Owusu, A. Aboalazayem, R. Aboulhosn, S. Abu Oda, A. Abubakar, A. Abutaka, D. Acevedo Fontalvo, S. Acuna, A. Adefemi, S. Adegbola, T. Adenuga, A. Adeyeye, A. Adil Hilmi, A. Adisa, K. Aditya, T. Adjeso, R. Aftab, A. Afzal, V. Aggarwal, A. Aggarwal, R. Aguilera, M. -L. Aguilera-Are´valo, E. J. Aguirre Salamanca, I. Aguirre-Allende, D. Ahari, H. Ahmad, F. Ahmad Rauf, A. Ahmad Zartasht Khan, S. Ahmed, N. Ahmed Fieturi, S. Ahmed Mohamed, Z. Ahmed-Bakhsh, M. Ahsan Javed, L. Akano, A. Akbar, M. Akhbari, P. Akhmedov, G. Aksit, Y. Akula, A. S. Alagaratnam, S. Al Majid, O. Al Mukhtar, H. Al Omran, N. AlAsali, M. Al-Azzawi, R. Al-Habsi, H. Al-Iraqi, H. Al-Naggar, E. Alameer, H. Albirnawi, D. Alderson, F. Aldulaijan, R. Alejandro Miranda Ojeda, A. AlHasan, S. Ali, A. Ali, M. Ali Khan, Y. Alimova, F. Aljanadi, R. Aljubure, N. Allopi, H. Almedbal, M. Almubarak, Z. Alqaidoom, N. Alselaim, M. Alshaar, R. Alshammari, K. Altaf, S. Altıner, B. Altunpak, L. A. Alvarez Lozada, E. Amal Nahal, A. Amer, K. Amin, U. Aminu, N. Amisi Numbi, T. Amjad, R. Amoah, Y. An, N. -A. Anastasopoulos, J. Andre´s Urrutia, F. Angarita, K. -L. Angarita, M. A´ ngel FreirI´a Eiras, A. Antypas, M. A. Anwar, H. Anwar, T. O. Apampa, K. Apostolou, C. Aquina, R. Arachchige Adithi Himika Randeni, M. I. Archila Godı´nez, O. Arez, A. A. Arezzo, P. Armonis, S. Arshad, M. Arshad Salman, A. Arshid, P. C. Arteaga Asensio, T. Arthur, A. Arumuga Jothi, F. Aryo Damara, L. Asensio Gomez, J. Ashcroft, S. Ashraf, A. Asif, M. Atif, M. Attaullah Khan, N. Avellaneda, S. Awad, M. Awadh, A. Axiaq, A. Ayad Mohammed Shuwayyah, D. Ayalew, E. Aytac, F. Azam, J. Azevedo, B. Azhar, J. Aziz, A. Aziz, A. Azzam, A. Baba Ndajiwo, M. Baig, D. Baker, F. Bakko, R. Balachandran, G. Balachandran, J. Balagizi Mudekereza, E. Balai, B. Balci, A. Balduzzi, A. Balhareth, S. Bandyopadhyay, D. Banerjee, D. Bangalore Mahalinga, B. Bankhead-Kendall, N. D. A. Bankole, V. Banwell, F. Baris Bengur, B. Baris Ozmen, M. Barnard, R. Barnett, J. A. Barreras Espinoza, A. Barrios, G. Bass, M. Bass, A. Bausys, A. Bavikatte, J. Bayram, M. Belousov, A. G. Berardi, A. Beamish, C. Beattie, F. Belia, V. Bellato, S. Bellikatti, S. Benjamens, C. Benlice, S. Bennedsgaard, S. Bennett, Z. Bentounsi, H. Bergenfeldt, A. Bergenfelz, M. Besselink, G. Bhandoria, E. Bhangu, M. Bhatia, M. T. Bhatti, Z. Bilgili, G. Bislenghi, C. Bisset, S. Biswas, J. Blake, R. Blanco, L. Boccalatte, R. Boden, C. Bojanic, M. Boland, P. Boland, E. Bollen, E. -A. Bonci, L. Boni, A. Booth, R. Booth, A. Borakati, G. E. Borunda Escudero, S. J. Bosco, P. Bostro¨ m, P. Botelho de Alencar Ferreira Cruz, K. Bouchagier, A. Bouhuwaish, M. Boutros, K. Boyce, C. Boyle, L. Bradshaw, A. Brandl, A. Brar, G. Brat, H. Brenkman, C. Brennan, C. Brines, A. Brookmyre, C. Brosnan, L. Brouwers, A. Brown, L. Brown, C. Brown, J. Brown, V. BS, M. Buksh, M. Bunani Emmanuel, D. Burbano, A. Burelli, A. Burke, J. Burke, N. Burlov, A. Burns, O. Burton, A. Butt, B. Buzra Ozkan, L. Cabrera Silva, E. Y. Caicedo, T. Calderbank, W. Cambridge, G. Campelo, O. Can Tatar, F. Carbone, F. Carrano, D. Casallas, D. Casanova Portoles, F. Casciani, I. Cassimjee, O. A. Castaneda Ramı´rez, V. Catala´ n, J. Caviedes, L. Cayetano, M. ~ Ceresoli, M. Chan, V. Chan, P. Chandrasinghe, S. Chapman, A. Chaturvedi, D. Chaudhry, H. Chaudry, H. W. Chen, A. Cheng, M. Chernykh, A. M. Cherrie, I. Cheruiyot, J. Cheung, C. Chia, J. Chica, N. Chinai, A. Chirwa, J. Chiwaligo, A. Choi, J. Choi, M. R. Chowdhury, E. Christopher, N. Christou, T. Chu, D. Chua, H. W. Chua, C. Chung, A. Cihat Yildirim, M. Cillo, S. Cioffi, H. Claireaux, S. Clermonts, R. Clifford, M. Climent, A. Clynch, R. -J. Coelen, E. Cola´ s-Ruiz, A. Collar, M. Collard, K. C. Conlon, T. Connelly, K. Connor, J. A. Cook, T. Correia de Sa´, N. Cos¸gun Acar, T. Costa, D. Couch, S. Cowper, B. Creavin, B. Crook, A. Curell, R. D’alessio, J. Dale, J. Damgaard Eriksen, I. Dario Martin Gonzalez, A. Darwish, M. Das, R. Das, K. Das, R. Dave, S. O. David, T. Davies, C. Davis, S. Davison, V. Davletshina, A. Dawidziuk, A. Dawson, M. de Andres Crespo, H. de Berker, P. de Dieu Ngo, E. Dekker, R. de la Caridad Espinosa Luis, B. de Lacy, N. Demartines, A. de Montserrat Medina Sifuentes, S. De Silva, C. del Rio, V. Delaune, A. Dell, I. Demirbas¸, S. Demirli Atici, M. Deniz Tepe, M. Derebey, G. Desai, M. Desai, S. Devarakonda, N. Deveras, G. Di Franco, M. Di Martino, F. Di Marzo, A´ . Dı´az, G. Diaz del Gobbo, C. DiazCastrillon, L. Dick, K. Dickinson, E. Diego, I. Dimasi, A. Ding, S. Dingemans, L. Dixon, B. Dixon, W. Doherty, D. Dooreemeah, C. Donohue, M. Dornseifer, F. Dossa, W. Dossou, T. Drake, I. Drami, G. Drevin, M. C. du Plessis, N. Dudi-Venkata, R. Dudley, S. Duffy, D. Duklas, B. -D. Dumbrava, F. Duygu Avlar, A. Dworzynska, W. Ebrahim, A. Ebrahim, E. Efre´n Lozada Herna´ ndez, N. Ehigie, M. El Boghdady, C. El Hasnaoui, M. El Sheikh, A. El-Hussuna, O. Eldurssi, H. Elfeki, M. Elhadi, M. Elhassan, A. Elhissi, B. Elliot, C. Elsenbroek, B. Elsolh, N. Elson, H. Eltyeb, H. Emerson, S. H. Emile, G. Endalle, W. English, C. Ercisli, G. Espinosa, M. Essam Abdelraheem, H. Essangri, P. Etienne, M. D. Evans, T. Evans, C. Ezeme, F. Ezzahraa, T. Fadalla, J. Fagan, M. Fahmy, C. Fairfield, O. Falade, S. Famularo, F. Faqar-Uz-Zaman, Y. Farid, A. Farooq, H. Farooq, F. Farooqui, B. Farquharson, A. Faruqi, R. Faulder, M. Faut, K. Fechner, T. Feenstra, M. Fehervari, L. Fernandez, J. Ferna´ ndez Alberti, L. Ferrario, D. Field, L. Fiore, S. Fingerhut, S. Finlayson, N. Fleming, C. Fleming, E. Florial, M. Fok, D. Fokin, M. Foley, M. P. Forero, T. Forgan, M. Fornasiero, H. Fowler, G. Fowler, E. Franchi, L. Franklin, A˚ . Fredriksson, P. Fruhling, G. Fuentes Navarrette, A. Fu¨ lo¨ p, M. Furtado, T. Gaarder, N. Galbraith, I. T. K. Gallagher, G. Gallo, T. Gana, E. Gaskin, M. Gasparini, R. G. Gatan, E. Geary, K. Gelaye Wudineh, G. Gemenetzis, M. Georgi, H. Ghalige, W. Ghareeb, T. Ghatwary Tantawy, C. Ghomsi, A. Ghuman, P. Giannakis, F. Giron, K. Gjengedal, E. Gkotsis, J. Glasbey, S. Godahewa, D. Godula, P. Goffredo, S. Goh, M. Golriz, L. Gomez, D. Gomez Gomez, R. Gonzalez, D. Gonzalez, E. Gonzalez Gutierrez, D. Gopar, L. Gordini, A. Gori, S. Gorta´ zar, N. Gousy, R. Gowda, M. Gowda, J. Gqada, M. Grechenig, J. Greer, L. Grego´ rio, A. Grigorova, H. Grimes, V. Groot, R. C. Grossman, R. Gruber, A. Gru¨ ter, R. Guest, R. Gujjuri, E. Gu¨ lc¸ek, B. Gulcu, K. Gull, M. Gulmez, V. Gupta, A. Gutlic, T. Guven, T. Gwatirisa, G. Gwini, P. Gwodog, S. Gysling, M. Habib, A. B. Hafeez Bhatti, J. Hallesmith, S. Halloran, M. Hamza Sadiq, C. Haney, N. Hanna, L. Hanna, M. Hannington, J. Harbjerg, D. Haribaskaran, N. Harran, B. Harrington, E. Harrison, R. Hasan, S. Hashmi, M. Hassan, A. Hassan, L. Haverkamp, S. Hazen, B. Heer, J. Heil, J. Helliwell, N. Henriksen, D. Henshall, M. Hermanson, S. Hermena, D. Hettiarachchi, C. Hextall, M. Hidalgo, H. Hidayat, A. Hider, P. Higgins, R. Hinchliffe, D. Hirani, D. Hirpara, I. Hisham, M. Hite, S. M. Hoh, C. Holmberg, E. Ho¨ lmich, F. Holst, A. Hossam, A. Hossam Elfallal, P. Howard, E. Huaman, Y. Huang, L. Huang, D. Huang, T. Huber, J. Hugh, J. Hughes, F. Hu¨ ttner, R. Huynh, A. Hylands, J. Iannuzzi, B. Ielpo, A. Iftikhar Talib, J. Ignacio, P. Ignatavicius, S. Ike, C. Ikwu, M. Inama, A. Ing, A. Ingels, A. Isik, N. Islam, I. J. Ives, A. J. M. S. AlHasan, C. J. Perez Rivera, F. Ja´ come, T. Jaffer, O. Jagiella-Lodise, M. Jain, K. Jain, M. Jakubauskas, M. Jalal, H. James, Y. Jang, B. Janssen, H. Jansson, U´ . Jariod-Ferrer, H. Javanmard, S. Javed, U. Jayarajah, I. Jayasuriya, J. Je, Z. Jessop, E. Jia Lin Tang, H. Jiang, Y. Jiayan, T. Jih Huei, R. Jimenez-Rodriguez, D. Joh, A. Johnson, N. Jones, C. Jones, C. Jordan, J. Jose´ Nu´ nez Ju, ~ M. Jose´ Pizarro, C. Jose Salazar J. Joseph, C. Justiniano, T. Kabir, M. Kadhum, C. Kalfountzos, E. Kalogiannaki, K. Kalyanasundaram, S. Kamarajah, M. Kamil Quraishi, Y. Kanemitsu, A. Kapila, V. Kapila, G. Karagiannidis, M. Kashif, S. Kathiravelupillai, A. Kathiravelupillai, E. Katsogridakis, K. Kaur, H. Kaur Sekhon Inderjit Singh, N. Kausur, M. Kawka, G. Keehan, S. Kehlet Watt, M. Kelly, M. E. Kelly, I. Kelvin Egbuchulem, G. Kembuan, E. Khajeh, A. Khaled Elfaitur, M. F. Khan, S. Khan, M. Khan, D. Khan, H. Khan, H. Khatkar, E. Khatkov, R. Khaw, B. Kim, K. Kishore Siddiraju, D. Kitua, B. Kırımtay, S. Kmezic, S. Knight, T. Koe¨ter, A. Koh, F. Koh Hong Xiang, T. Kojo Anyomih, A. I. N. Kok, R. Kokelaar, I. Koliarakis, S. Kolli, J. Kong, D. Ko¨ nig, M. otze, A. Kourdouli, M. Kowal, A. Kraima, F. Kramer, M. Kryzauskas, I. Kuchynskyi, C. Kuemmerli, S. Kuiper, S. Kumar, A. Kumar, L. Kumar, H. Kumar, N. Kumar, S. Kumar Bandyopadhyay, P. Kumar Garg, S. Kumar Venkatappa, J. Kung, S. Kural, A. Kushairi, E. Kuuzie, M. Kvietkauskas, I. Kwek, J. La, L. Lai, S. Lakpriya, K. Lam, M. Lami, I. Lansdorp-Vogelaar, P. Lapolla, H. Larsen, J. Latif, U. Laudari, A. Laurnezi, A. Lawal, S. Lawday, H. Lederhuber, A. Lednev, R. Lee, M. E. van Leerdam, G. Lefevbre, M. Lesmus, F. A. Leyva Moraga, E. Leyva Moraga, F. Leyva Moraga, H. L. Li, A. Li, Z. Li, E. Licardie, A. Light, A. L. Lightner, A. Lin, E. Lincango, F. Litta, H. Liu, B. Lofthouse, M. A. Londono, R. Lopes, R. Lopes de Freitas, L. Lopez, A. I. Lo´ pez, J. ~ Lopez-Gomez, G. Lopez-Pena, R. Lowe, D. Lowe, M. Lowey, G. Loy, V. Lozanovski, J. Luzon, P. Lynn, T. Maccabe, A. Machielsen, C. A. Mafla Herrerı´a, L. Maggino, K. Mahawar, D. Mahmood, M. Mahmoud, K. Mahtani, I. Maitra, S. Maji, I. Majiet, L. Mal, J. Malherbe, K. Malhotra, P. Malkomes, E. Man, A. Manan Sheikh, S. Manjunath, R. Manzano Nunez, S. Manzoor, R. Maqsood, G. ~ Marchegiani, F. Marchegiani, D. Marı´n, A. Marin, I. Marks, E. Marson, A. Martensen, D. Martin, G. Martı´n Martı´n, B. Martin-Perez, P. Martinez, P. Marwaha, C. Mashauri, H. Mashbari, Ł. Masior, R. Masri, L. Masud, S. Masudi, G. Mateu Calabuig, S. Math, A. Matrachisia, J. Mayol, D. Mazingi, A. Mazzotta, J. McAlinden, G. McCabe, L. McColm, H. McElvaney, K. McGivern, J. McGovern, E. McGuinness, N. McInerney, S. Mckay, C. McKee, M. McKenna, N. McKenna, K. McLean, S. Mediratta, Y. Medkova, O. Medzhidov, A. Mehraj, M. Mekhael, O. Mekinde, C. Mellenthin, A. Melucci, K. Mentor, J. Merchant, H. Messias, M. Messeha, C. Meza, P. Mhango, M. Miladinov, M. Milagros Niquen Jimenez, P. Miller, E. Mills, A. Milton, O. A. Minayeva, Z. MinHua Zheng, H. Mischlinger, B. Mo¨ ckli, R. Modi, H. M. Mohamed, M. Mohamed, T. Mohamed Abulghasm, S. A. Mohammad, T. O. Mohammed, A. Mohammed, H. Mohan, M. Mohan, I. Moin, V. Mok, G. Molina, J. Moloney, J. Moneim, M. Monfort Mira, B. Montcusı´ Ventura, M. Montouri, M. Moossdorff, I. Mora-Guzma´ n, B. Moran, R. A. R. Mora´ n, S. Moreno-Ordaz, A´ . Morera, R. Morgan, R. Morley, D. Moro-Valdezate, S. Moros, J. -L. Moss, A. Morven, D. Morton, A. Moynihan, M. Moyo´ n, N. Muduli, N. Mugla, W. Mugla, P. Mu¨ ller, G. Mun, R. Mundhada, I. Munir, F. Munoz, E. Mu ~ noz, A. Mu ~ noz, D. ~ C. Munoz Balderas, E. Murgitroyd, V. Murray, S. Murthy, W. ~ Mushiwokufa, H. Mustafa, B. Mustakimov, P. Mutambanengwe, P. Myint, S. Nadkarni, P. A. Naess, S. Nahar, P. Naidoo, R. Nam, S. Nandhra, N. Nanjappa, V. Narasimhan, W. Nardi, M. Nasir, A. Naughton, D. Naumann, S. Navarro, M. Nawaaz Karimbocus, A. Nazir, S. Ndereya, A. Ndong, I. Negoi, D. Nel, D. Nelson, S. Nepal, T. Nugent, D. Nepogodiev, J. Neufeld, J. Ng, D. Ng, C. E. Ng, S. Ngaserin, L. Ngu, E. Ngwenya, R. N. Fhearaigh, T. -K. Nikolousakis, M. Ninkovic, G. Nita, C. Nitschke, E. Noren, T. Noton, A. Novikova, Z. Nowinka, T. Nyakunengwa, A. Nyalundja, I. Nzenwa, H. Ø Kristensen, C. O’Brien, L. O’Brien, S. O’Brien, J. O’Reilly, S. O’Rourke, M. O’Sullivan, M. O’Dwyer, L. Ochieng, E. Oderoha, K. E. Oh, L. O¨ hlberger, M. O¨ lc¸u¨ m, A. Olkina, M. Omkumar, B. Omnitel, D. Oncel Yakar, K. Ong, L. Ong Wei Lin, R. Ooi, S. Ooi, A. Oomman, D. Oon Tyjet, S. Opiyo, J. J. Oscullo Yepez, N. Osei-kuffour, T. Osunronbi, A. Ottlaka´ n, S. Oussama Kacimi, S. Ovaere, A. Ozair, F. Pachler, S. Pai Oo, S. Paiella, L. Panaiotti, N. Panda, S. Pandarinath, D. Pandey, S. Pandrowala, F. Papa Mamadou, M. Paranathala, J. Park, C. Parmar, A. Parvez, L. Pasovic, A. Pasquer, N. Pasumarthy, F. Pata, T. Patel, P. Patel, N. Patel, M. Patel, N. Patron Uriburu, R. Patrone, A. Paul, O. M. Pavan Kumar, A. Pavithran, M. Pedraza Ciro, G. Pellino, A. Peloso, M. T. Pena~ Gallardo, A. Pena Velazquez, J. Perea, L. E. Pe´rez-Sa´ nchez, T. ~ Perra, G. Perrotta, P. Petersson, G. Petra, N. Petrucciani, C. Pickin, V. Pino, E. Pinotti, F. Pinto, P. Plum, F. Podesta, T. Pollini, M. Pompeu Sa´, F. Ponce Leon, H. S. Ponniah, X. Ponte de Sousa, J. Ponton, A. Pontula, M. Popa, A. L. Portilla, F. Posner, S. Post, A. Potolicchio, S. Pouwels, A. Povo, P. Prasad, S. Preciado, R. Preece, D. Proud, J. A. Pulido Segura, N. Puliyath, M. Qui, A. S. Quimbaya Rodrı´guez, W. Raby-Smith, A. Racovit¸a, A. Rad, R. Radwan, M. Rafaih Iqbal, A. Rafik, B. Raguan, M. Rahi, J. -L. Rahiri, J. Rahme, L. Rai, A. Raj, A. Raj Saksena, M. Raja, J. Ramirez, J. Ramzi, J. Ranstam, C. Rao, A. Rashid, B. Ratnayake, K. Rattanasirivilai, K. Raubenheimer, N. Ravikumar, S. Ravn, N. Razoz, W. Rea, A. Regan, M. Rela, A. Remme, C. E. Rey Chaves, A. Reyes, A. Riad, D. Rice, K. Rios Quintana, A. Ritter, M. Roalsø, D. Robinson, J. Rodriguez, F. Rodrı´guez, M. C. Rodriguez, A. Rogers, J. Rohila, D. Romanyuc, I. Romic, M. Rommaneh, G. Rompianesi, F. Rosa, F. Roscio, A. Rose, T. Rotimi, H. Ruiz, J. Ruiz Yucuma, E. Ruiz-U´ car, M. Ruslan, M. Rutega˚ rd, E. Ryan Harper, A. Ryckx, D. Rydbeck, E. Fonseca, A. Sanchez Teran, S. Sanchez Ussa, O. Sandli, H. Sanfey, J. Sanghera, I. Sani, M. Santafe Guerrero, M. Sante Fornasiero, O. Santes Jasso, I. Santos Pereira, H. Santos Sousa, A. Saratzis, A. Sarmiento Alarcon, T. Saumtally, R. Sayyed, M. Schettino, L. Schleimer, T. Schmidt, K. Schondffelt, M. Schwab, A. Scott, H. Searle, L. Sebopelo, B. Seeglier, R. Seishima, D. Semenvov, A. Senent-Boza, J. Sepulveda, M. Serenari, M. Serrano Navidad, I. Sert, E. Sewart, A. Sgro`, V. Shadrina, K. Shah, F. Shahid, M. Shalaby, B. Shankar, J. Shapiro, L. Sharma, A. Sheel, A. Shenfine, S. Shenoy, A. Sherif, N. Shetty, R. Shetty, T. C. Sia, D. Sichimba, H. Siddique, I. Siddiqui, G. Simkens, J. Simoe, H. Simon, L. Sinan, T. Singh, K. Singh, Y. Singh, L. Sinha, L. Siragusa, T. Sluckin, Y. W. Smart, H. Smith, K. Smith, L. Smits, C. Sneep-van Kessel, C. Sohrabi, O. Solo´ rzano Pineda, A. Soma, L. Sooriyapiragasam, K. Søreide, M. Sparavigna, R. Spence, N. Spencer, H. Spiers, A. Spinelli, J. Sprakel, S. Sravanam, M. Srinivasan, R. Srinivasan, A. Staniszewska, S. J. Stanworth, K. Stasinos, R. J. C. Steele, I. Steinholt, M. Steinruecke, B. -J. Stephen, J. Stijns, M. Still, W. Stupalkowska, S. Subba, V. V. Subbotin, P. Sucharitkul, A. Sudarsanam, D. Sudhamsh Reddy, T. Suhardja, M. Suliman, M. Sund, A. Sunilkumar, N. Suresh, S. Sussmes, P. Sutton, J. Syltern, A. Taha, Y. Takamizawa, A. B. Takoutsing Dongmo, T. Tama´ s, L. Tan, J. L. Tan, K. Tan, E. Tan, A. Tan Yong Hui, A. Tanase, A. Tariverdiev, A. Tasnem, C. Tatar, E. Tay, P. Tejedor, G. Tesfaye, F. Tetinou, C. Thorpe, A. Thyø, D. Tlelo Amastal, M. Tolani, K. Tolga Saracoglu, T. To¨ lgyes, J. Tong, L. Torrent Jansa`, S. Toscano Igartua, M. R. Tovani Palone, H. Traff, J. Trevis, W. Tummers, A. Tur, I. Turchenko, V. Uche, A. Uddin, N. Udonsak, M. Ullah, T. Urbonas, C. Uwins, E. Uy Magadia, A. Uzair Qureshi, K. Uzun, P. Vadim, G. Valarche, R. A. Valdez Gonzalez, M. Vallee, D. -J. van Beek, A. S. van Dalen, D. van den Hondel, E. van der stok, M. van Dorp, S. van Oostendorp, E. van Praag, J. van Rees, L. van Silfhout, Z. Varga, S. Varghese, C. Varghese, J. Varghese, A. -M. Vasilica, X. Va´ squez Ojeda, E. Vega, S. Vehler, R. Venchiarutti, S. Vengatesan, M. Venn, D. Verma, G. Vianey Partida Nava, D. Victoria, P. Vieira, M. E. Vilar Alvarez, D. Vinci, G. Viscasillas Palla` s, M. Viswanath, J. Vivanco, V. Vizcaya Rodrı´guez, J. Vo, D. Volchanski, T. Voron, Y. Voronovskyi, J. Vu, M. Wadhwa, S. Wadhwa, G. Wagner, M. Wallace, Y. Y. Wang, J. Wang, A. Wani, K. Wanigasooriya, S. Wanjara, N. Wanjiku, C. Warner, T. Wei Leow, T. Weiser, M. Weisters, M. J. Wellington, C. Wells, C. Wenzelberg, D. Wettstein, A. Wezel, L. Wheldon, L. Widmer, M. Wilson, S. Wigmore, T. Wijayaratne, M. Wijeyaratne, B. P. L. 1176 | BJS, 2021, Vol. 108, No. 10 Sá-Marta, I. Sadien, D. SafariNteranya, K. Sagoo, S. Sakata, E. Saladino, A. Saleem, S. Saleem, M. Salehi, S. Salih, V. Sallinen, S. Salvans, Z. H. Sam, E. Samadov, M. Sampaio Alves, A. Sanad, S. Sánchez Wijnhoven, R. Wilkin, E. Williams, F. Willis, D. Winter, M. M. Wirsik, B. Wishah, G. Wong, W. J. Wong, K. Wong, K. -Y. Wong, D. Worku, E. Wright, J. Wright, O. Wroe Wright, S. Xenacki, W. Xia, W. Xu, Z. Xu, A. Yalcinkaya, W. Yang, P. -C. Yang, A. Yanishev, A. Yanzon de la Torre, H. Yao, E. Yaqoob, S. Yen Ling Quake, D. Yeo, B. Yeom, D. Yershov, M. Yiasemidou, A. Yildiz, A. Yiu, M. Yoav, E. Yong, R. Yoshimura, M. U. Younis, Z. Younis Ringshawl, M. Youssef, Y. Yue, S. Yuen, R. Yuldashev, C. Yurttas, B. Yves, A. Zaborowski, R. Zackeri, A. Zafar, W. Zahra, A. Zaidi, S. Zainudin, R. Zakeri, I. Zamora, A. T. Zamora, M. Zawistowski, G. Zbikowska, W. Zegers, S. Zehra, A. Zeyra, Z. Zhagniyev, L. G. Zhukova, M. Zivanovic, J. Zmuc, M. Zope, A. Zubayraeva, B. Zucker., Abahuje, E., Abbas, A., Abd El Aziz Abd El Maksoud, M., Abdelhady, A., Abdelhamid, S., Abdelkarem Ahmed Faraj, H., Abdelqader, B., Abdelrahman, T., Abdou, H., Abdullah, A., Abedua Harrison, M., Abem Owusu, E., Aboalazayem, A., Aboulhosn, R., Abu Oda, S., Abubakar, A., Abutaka, A., Acevedo Fontalvo, D., Acuna, S., Adefemi, A., Adegbola, S., Adenuga, T., Adeyeye, A., Adil Hilmi, A., K. Aditya, A. Adisa, Adjeso, T., Aftab, R., Afzal, A., Aggarwal, V., Aggarwal, A., Aguilera, R., Aguilera-Are´valo, M. -L., Aguirre Salamanca, E. J., Aguirre-Allende, I., Ahari, D., Ahmad, H., Ahmad Rauf, F., Ahmad Zartasht Khan, A., Ahmed, S., Ahmed Fieturi, N., Ahmed Mohamed, S., Ahmed-Bakhsh, Z., Ahsan Javed, M., Akano, L., Akbar, A., Akhbari, M., Akhmedov, P., Aksit, G., Akula, Y., Alagaratnam, A. S., Al Majid, S., Al Mukhtar, O., Al Omran, H., Alasali, N., Al-Azzawi, M., Al-Habsi, R., Al-Iraqi, H., Al-Naggar, H., Alameer, E., Albirnawi, H., Alderson, D., Aldulaijan, F., Alejandro Miranda Ojeda, R., Alhasan, A., Ali, S., Ali, A., Ali Khan, M., Alimova, Y., Aljanadi, F., Aljubure, R., Allopi, N., Almedbal, H., Almubarak, M., Alqaidoom, Z., Alselaim, N., Alshaar, M., Alshammari, R., Altaf, K., Altıner, S., Altunpak, B., Alvarez Lozada, L. A., Amal Nahal, E., Amer, A., Amin, K., Aminu, U., Amisi Numbi, N., Amjad, T., Amoah, R., An, Y., Anastasopoulos, N. -A., Andre´s Urrutia, J., Angarita, F., Angarita, K. -L., A´ ngel FreirI´a Eiras, M., Antypas, A., Anwar, M. A., Anwar, H., Apampa, T. O., Apostolou, K., Aquina, C., Arachchige Adithi Himika Randeni, R., Archila Godı´nez, M. I., Arez, O., Arezzo, A. A., Armonis, P., Arshad, S., Arshad Salman, M., Arshid, A., Arteaga Asensio, P. C., Arthur, T., Arumuga Jothi, A., Aryo Damara, F., Asensio Gomez, L., Ashcroft, J., Ashraf, S., Asif, A., Atif, M., Attaullah Khan, M., Avellaneda, N., Awad, S., Awadh, M., Axiaq, A., Ayad Mohammed Shuwayyah, A., Ayalew, D., Aytac, E., Azam, F., Azevedo, J., Azhar, B., Aziz, J., Aziz, A., Azzam, A., Baba Ndajiwo, A., Baig, M., Baker, D., Bakko, F., Balachandran, R., Balachandran, G., Balagizi Mudekereza, J., Balai, E., Balci, B., Balduzzi, A., Balhareth, A., Bandyopadhyay, S., Banerjee, D., Bangalore Mahalinga, D., Bankhead-Kendall, B., Bankole, N. D. A., Banwell, V., Baris Bengur, F., Baris Ozmen, B., Barnard, M., Barnett, R., Barreras Espinoza, J. A., Barrios, A., Bass, G., Bass, M., Bausys, A., Bavikatte, A., Bayram, J., Belousov, M., Berardi, A. G., Beamish, A., Beattie, C., Belia, F., Bellato, V., Bellikatti, S., Benjamens, S., Benlice, C., Bennedsgaard, S., Bennett, S., Bentounsi, Z., Bergenfeldt, H., Bergenfelz, A., Besselink, M., Bhandoria, G., Bhangu, E., Bhatia, M., Bhatti, M. T., Bilgili, Z., Bislenghi, G., Bisset, C., Biswas, S., Blake, J., Blanco, R., Boccalatte, L., Boden, R., Bojanic, C., Boland, M., Boland, P., Bollen, E., Bonci, E. -A., Boni, L., Booth, A., Booth, R., Borakati, A., Borunda Escudero, G. E., Bosco, S. J., Bostro¨ m, P., Botelho de Alencar Ferreira Cruz, P., Bouchagier, K., Bouhuwaish, A., Boutros, M., Boyce, K., Boyle, C., Bradshaw, L., Brandl, A., Brar, A., Brat, G., Brenkman, H., Brennan, C., Brines, C., Brookmyre, A., Brosnan, C., Brouwers, L., Brown, A., Brown, L., Brown, C., Brown, J., Bs, V., Buksh, M., Bunani Emmanuel, M., Burbano, D., Burelli, A., Burke, A., Burke, J., Burlov, N., Burns, A., Burton, O., Butt, A., Buzra Ozkan, B., Cabrera Silva, L., Caicedo, E. Y., Calderbank, T., Cambridge, W., Campelo, G., Can Tatar, O., Carbone, F., Carrano, F., Casallas, D., Casanova Portoles, D., Casciani, F., Cassimjee, I., Castaneda Ramı´rez, O. A., Catala´ n, V., Caviedes, J., Cayetano, L., ~ Ceresoli, M., Chan, M., Chan, V., Chandrasinghe, P., Chapman, S., Chaturvedi, A., Chaudhry, D., Chaudry, H., Chen, H. W., Cheng, A., Chernykh, M., Cherrie, A. M., Cheruiyot, I., Cheung, J., Chia, C., Chica, J., Chinai, N., Chirwa, A., Chiwaligo, J., Choi, A., Choi, J., Chowdhury, M. R., Christopher, E., Christou, N., Chu, T., Chua, D., Chua, H. W., Chung, C., Cihat Yildirim, A., Cillo, M., Cioffi, S., Claireaux, H., Clermonts, S., Clifford, R., Climent, M., Clynch, A., Coelen, R. -J., Cola´ s-Ruiz, E., Collar, A., Collard, M., Conlon, K. C., Connelly, T., Connor, K., Cook, J. A., Correia de Sa´, T., Cos¸gun Acar, N., Costa, T., Couch, D., Cowper, S., Creavin, B., Crook, B., Curell, A., D’Alessio, R., Dale, J., Damgaard Eriksen, J., Dario Martin Gonzalez, I., Darwish, A., Das, M., Das, R., Das, K., Dave, R., David, S. O., Davies, T., Davis, C., Davison, S., Davletshina, V., Dawidziuk, A., Dawson, A., de Andres Crespo, M., de Berker, H., de Dieu Ngo, P., Dekker, E., de la Caridad Espinosa Luis, R., de Lacy, B., Demartines, N., de Montserrat Medina Sifuentes, A., De Silva, S., del Rio, C., Delaune, V., Dell, A., Demirbas¸, I., Demirli Atici, S., Deniz Tepe, M., Derebey, M., Desai, G., Desai, M., Devarakonda, S., Deveras, N., Di Franco, G., Di Martino, M., Di Marzo, F., Dı´az, A´., Diaz del Gobbo, G., Diazcastrillon, C., Dick, L., Dickinson, K., Diego, E., Dimasi, I., Ding, A., Dingemans, S., Dixon, L., Dixon, B., Doherty, W., Dooreemeah, D., Donohue, C., Dornseifer, M., Dossa, F., Dossou, W., Drake, T., Drami, I., Drevin, G., du Plessis, M. C., Dudi-Venkata, N., Dudley, R., Duffy, S., Duklas, D., Dumbrava, B. -D., Duygu Avlar, F., Dworzynska, A., Ebrahim, W., Ebrahim, A., Efre´n Lozada Herna´ ndez, E., Ehigie, N., El Boghdady, M., El Hasnaoui, C., El Sheikh, M., El-Hussuna, A., Eldurssi, O., Elfeki, H., Elhadi, M., Elhassan, M., Elhissi, A., Elliot, B., Elsenbroek, C., Elsolh, B., Elson, N., Eltyeb, H., Emerson, H., Emile, S. H., Endalle, G., English, W., Ercisli, C., Espinosa, G., Essam Abdelraheem, M., Essangri, H., Etienne, P., Evans, M. D., Evans, T., Ezeme, C., Ezzahraa, F., Fadalla, T., Fagan, J., Fahmy, M., Fairfield, C., Falade, O., Famularo, S., Faqar-Uz-Zaman, F., Farid, Y., Farooq, A., Farooq, H., Farooqui, F., Farquharson, B., Faruqi, A., Faulder, R., Faut, M., Fechner, K., Feenstra, T., Fehervari, M., Fernandez, L., Ferna´ ndez Alberti, J., Ferrario, L., Field, D., Fiore, L., Fingerhut, S., Finlayson, S., Fleming, N., Fleming, C., Florial, E., Fok, M., Fokin, D., Foley, M., Forero, M. P., Forgan, T., Fornasiero, M., Fowler, H., Fowler, G., Franchi, E., Franklin, L., Fredriksson, A˚., Fruhling, P., Fuentes Navarrette, G., Fu¨ lo¨ p, A., Furtado, M., Gaarder, T., Galbraith, N., Gallagher, I. T. K., Gallo, G., Gana, T., Gaskin, E., Gasparini, M., Gatan, R. G., Geary, E., Gelaye Wudineh, K., Gemenetzis, G., Georgi, M., Ghalige, H., Ghareeb, W., Ghatwary Tantawy, T., Ghomsi, C., Ghuman, A., Giannakis, P., Giron, F., Gjengedal, K., Gkotsis, E., Glasbey, J., Godahewa, S., Godula, D., Goffredo, P., Goh, S., Golriz, M., Gomez, L., Gomez Gomez, D., Gonzalez, R., Gonzalez, D., Gonzalez Gutierrez, E., Gopar, D., Gordini, L., Gori, A., Gorta´ zar, S., Gousy, N., Gowda, R., Gowda, M., Gqada, J., Grechenig, M., Greer, J., Grego´ rio, L., Grigorova, A., Grimes, H., Groot, V., Grossman, R. C., Gruber, R., Gru¨ ter, A., Guest, R., Gujjuri, R., Gu¨ lc¸ek, E., Gulcu, B., Gull, K., Gulmez, M., Gupta, V., Gutlic, A., Guven, T., Gwatirisa, T., Gwini, G., Gwodog, P., Gysling, S., Habib, M., Hafeez Bhatti, A. B., Hallesmith, J., Halloran, S., Hamza Sadiq, M., Haney, C., Hanna, N., Hanna, L., Hannington, M., Harbjerg, J., Haribaskaran, D., Harran, N., Harrington, B., Harrison, E., Hasan, R., Hashmi, S., Hassan, M., Hassan, A., Haverkamp, L., Hazen, S., Heer, B., Heil, J., Helliwell, J., Henriksen, N., Henshall, D., Hermanson, M., Hermena, S., Hettiarachchi, D., Hextall, C., Hidalgo, M., Hidayat, H., Hider, A., Higgins, P., Hinchliffe, R., Hirani, D., Hirpara, D., Hisham, I., Hite, M., Hoh, S. M., Holmberg, C., Ho¨ lmich, E., Holst, F., Hossam, A., Hossam Elfallal, A., Howard, P., Huaman, E., Huang, Y., Huang, L., Huang, D., Huber, T., Hugh, J., Hughes, J., Hu¨ ttner, F., Huynh, R., Hylands, A., Iannuzzi, J., Ielpo, B., Iftikhar Talib, A., Ignacio, J., Ignatavicius, P., Ike, S., Ikwu, C., Inama, M., Ing, A., Ingels, A., Isik, A., Islam, N., Ives, I. J., Alhasan, A. J. M. S., Perez Rivera, C. J., Ja´ come, F., Jaffer, T., Jagiella-Lodise, O., Jain, M., Jain, K., Jakubauskas, M., Jalal, M., James, H., Jang, Y., Janssen, B., Jansson, H., Jariod-Ferrer, U´., Javanmard, H., Javed, S., Jayarajah, U., Jayasuriya, I., Je, J., Jessop, Z., Jia Lin Tang, E., Jiang, H., Jiayan, Y., Jih Huei, T., Jimenez-Rodriguez, R., Joh, D., Johnson, A., Jones, N., Jones, C., Jordan, C., Jose´ Nu´ nez Ju, J., Jose´ Pizarro, ~ M., Joseph, C. Jose Salazar J., Justiniano, C., Kabir, T., Kadhum, M., Kalfountzos, C., Kalogiannaki, E., Kalyanasundaram, K., Kamarajah, S., Kamil Quraishi, M., Kanemitsu, Y., Kapila, A., Kapila, V., Karagiannidis, G., Kashif, M., Kathiravelupillai, S., Kathiravelupillai, A., Katsogridakis, E., Kaur, K., Kaur Sekhon Inderjit Singh, H., Kausur, N., Kawka, M., Keehan, G., Kehlet Watt, S., Kelly, M., Kelly, M. E., Kelvin Egbuchulem, I., Kembuan, G., Khajeh, E., Khaled Elfaitur, A., Khan, M. F., Khan, S., Khan, M., Khan, D., Khan, H., Khatkar, H., Khatkov, E., Khaw, R., Kim, B., Kishore Siddiraju, K., Kitua, D., Kırımtay, B., Kmezic, S., Knight, S., Koe¨ter, T., Koh, A., Koh Hong Xiang, F., Kojo Anyomih, T., Kok, A. I. N., Kokelaar, R., Koliarakis, I., Kolli, S., Kong, J., Ko¨ nig, D., Otze, M., Kourdouli, A., Kowal, M., Kraima, A., Kramer, F., Kryzauskas, M., Kuchynskyi, I., Kuemmerli, C., Kuiper, S., Kumar, S., Kumar, A., Kumar, L., Kumar, H., Kumar, N., Kumar Bandyopadhyay, S., Kumar Garg, P., Kumar Venkatappa, S., Kung, J., Kural, S., Kushairi, A., Kuuzie, E., Kvietkauskas, M., Kwek, I., La, J., Lai, L., Lakpriya, S., Lam, K., Lami, M., Lansdorp-Vogelaar, I., Lapolla, P., Larsen, H., Latif, J., Laudari, U., Laurnezi, A., Lawal, A., Lawday, S., Lederhuber, H., Lednev, A., Lee, R., van Leerdam, M. E., Lefevbre, G., Lesmus, M., Leyva Moraga, F. A., Leyva Moraga, E., Leyva Moraga, F., Li, H. L., Li, A., Li, Z., Licardie, E., Light, A., Lightner, A. L., Lin, A., Lincango, E., Litta, F., Liu, H., Lofthouse, B., Londono, M. A., Lopes, R., Lopes de Freitas, R., Lopez, L., Lo´ pez, A. I., ~ Lopez-Gomez, J., Lopez-Pena, G., Lowe, R., Lowe, D., Lowey, M., Loy, G., Lozanovski, V., Luzon, J., Lynn, P., Maccabe, T., Machielsen, A., Mafla Herrerı´a, C. A., Maggino, L., Mahawar, K., Mahmood, D., Mahmoud, M., Mahtani, K., Maitra, I., Maji, S., Majiet, I., Mal, L., Malherbe, J., Malhotra, K., Malkomes, P., Man, E., Manan Sheikh, A., Manjunath, S., Manzano Nunez, R., Manzoor, S., Maqsood, R., ~ Marchegiani, G., Marchegiani, F., Marı´n, D., Marin, A., Marks, I., Marson, E., Martensen, A., Martin, D., Martı´n Martı´n, G., Martin-Perez, B., Martinez, P., Marwaha, P., Mashauri, C., Mashbari, H., Masior, Ł., Masri, R., Masud, L., Masudi, S., Mateu Calabuig, G., Math, S., Matrachisia, A., Mayol, J., Mazingi, D., Mazzotta, A., Mcalinden, J., Mccabe, G., Mccolm, L., Mcelvaney, H., Mcgivern, K., Mcgovern, J., Mcguinness, E., Mcinerney, N., Mckay, S., Mckee, C., Mckenna, M., Mckenna, N., Mclean, K., Mediratta, S., Medkova, Y., Medzhidov, O., Mehraj, A., Mekhael, M., Mekinde, O., Mellenthin, C., Melucci, A., Mentor, K., Merchant, J., Messias, H., Messeha, M., Meza, C., Mhango, P., Miladinov, M., Milagros Niquen Jimenez, M., Miller, P., Mills, E., Milton, A., Minayeva, O. A., MinHua Zheng, Z., Mischlinger, H., Mo¨ ckli, B., Modi, R., Mohamed, H. M., Mohamed, M., Mohamed Abulghasm, T., Mohammad, S. A., Mohammed, T. O., Mohammed, A., Mohan, H., Mohan, M., Moin, I., Mok, V., Molina, G., Moloney, J., Moneim, J., Monfort Mira, M., Montcusı´ Ventura, B., Montouri, M., Moossdorff, M., Mora-Guzma´ n, I., Moran, B., Mora´ n, R. A. R., Moreno-Ordaz, S., Morera, A´., Morgan, R., Morley, R., Moro-Valdezate, D., Moros, S., Moss, J. -L., Morven, A., Morton, D., Moynihan, A., Moyo´ n, M., Muduli, N., Mugla, N., Mugla, W., Mu¨ ller, P., Mun, G., Mundhada, R., Munir, I., Munoz, F., Mu ~ noz, E., Mu ~ noz, A., Munoz Balderas, D. ~ C., Murgitroyd, E., Murray, V., Murthy, S., ~ Mushiwokufa, W., Mustafa, H., Mustakimov, B., Mutambanengwe, P., Myint, P., Nadkarni, S., Naess, P. A., Nahar, S., Naidoo, P., Nam, R., Nandhra, S., Nanjappa, N., Narasimhan, V., Nardi, W., Nasir, M., Naughton, A., Naumann, D., Navarro, S., Nawaaz Karimbocus, M., Nazir, A., Ndereya, S., Ndong, A., Negoi, I., Nel, D., Nelson, D., Nepal, S., Nugent, T., Nepogodiev, D., Neufeld, J., Ng, J., Ng, D., Ng, C. E., Ngaserin, S., Ngu, L., Ngwenya, E., Fhearaigh, R. N., Nikolousakis, T. -K., Ninkovic, M., Nita, G., Nitschke, C., Noren, E., Noton, T., Novikova, A., Nowinka, Z., Nyakunengwa, T., Nyalundja, A., Nzenwa, I., Ø Kristensen, H., O’Brien, C., O’Brien, L., O’Brien, S., O’Reilly, J., O’Rourke, S., O’Sullivan, M., O’Dwyer, M., Ochieng, L., Oderoha, E., Oh, K. E., O¨ hlberger, L., O¨ lc¸u¨ m, M., Olkina, A., Omkumar, M., Omnitel, B., Oncel Yakar, D., Ong, K., Ong Wei Lin, L., Ooi, R., Ooi, S., Oomman, A., Oon Tyjet, D., Opiyo, S., Oscullo Yepez, J. J., Osei-kuffour, N., Osunronbi, T., Ottlaka´ n, A., Oussama Kacimi, S., Ovaere, S., Ozair, A., Pachler, F., Pai Oo, S., Paiella, S., Panaiotti, L., Panda, N., Pandarinath, S., Pandey, D., Pandrowala, S., Papa Mamadou, F., Paranathala, M., Park, J., Parmar, C., Parvez, A., Pasovic, L., Pasquer, A., Pasumarthy, N., Pata, F., Patel, T., Patel, P., Patel, N., Patel, M., Patron Uriburu, N., Patrone, R., Paul, A., Pavan Kumar, O. M., Pavithran, A., Pedraza Ciro, M., Pellino, G., Peloso, A., Pena~ Gallardo, M. T., Pena Velazquez, A., Perea, J., Pe´rez-Sa´ nchez, L. E., ~ Perra, T., Perrotta, G., Petersson, P., Petra, G., Petrucciani, N., Pickin, C., Pino, V., Pinotti, E., Pinto, F., Plum, P., Podesta, F., Pollini, T., Pompeu Sa´, M., Ponce Leon, F., Ponniah, H. S., Ponte de Sousa, X., Ponton, J., Pontula, A., Popa, M., Portilla, A. L., Posner, F., Post, S., Potolicchio, A., Pouwels, S., Povo, A., Prasad, P., Preciado, S., Preece, R., Proud, D., Pulido Segura, J. A., Puliyath, N., Qui, M., Quimbaya Rodrı´guez, A. S., Raby-Smith, W., Racovit¸a, A., Rad, A., Radwan, R., Rafaih Iqbal, M., Rafik, A., Raguan, B., Rahi, M., Rahiri, J. -L., Rahme, J., Rai, L., Raj, A., Raj Saksena, A., Raja, M., Ramirez, J., Ramzi, J., Ranstam, J., Rao, C., Rashid, A., Ratnayake, B., Rattanasirivilai, K., Raubenheimer, K., Ravikumar, N., Ravn, S., Razoz, N., Rea, W., Regan, A., Rela, M., Remme, A., Rey Chaves, C. E., Reyes, A., Riad, A., Rice, D., Rios Quintana, K., Ritter, A., Roalsø, M., Robinson, D., Rodriguez, J., Rodrı´guez, F., Rodriguez, M. C., Rogers, A., Rohila, J., Romanyuc, D., Romic, I., Rommaneh, M., Rompianesi, G., Rosa, F., Roscio, F., Rose, A., Rotimi, T., Ruiz, H., Ruiz Yucuma, J., Ruiz-U´ car, E., Ruslan, M., Rutega˚ rd, M., Ryan Harper, E., Ryckx, A., Rydbeck, D., Fonseca, E., Sanchez Teran, A., Sanchez Ussa, S., Sandli, O., Sanfey, H., Sanghera, J., Sani, I., Santafe Guerrero, M., Sante Fornasiero, M., Santes Jasso, O., Santos Pereira, I., Santos Sousa, H., Saratzis, A., Sarmiento Alarcon, A., Saumtally, T., Sayyed, R., Schettino, M., Schleimer, L., Schmidt, T., Schondffelt, K., Schwab, M., Scott, A., Searle, H., Sebopelo, L., Seeglier, B., Seishima, R., Semenvov, D., Senent-Boza, A., Sepulveda, J., Serenari, M., Serrano Navidad, M., Sert, I., Sewart, E., Sgro`, A., Shadrina, V., Shah, K., Shahid, F., Shalaby, M., Shankar, B., Shapiro, J., Sharma, L., Sheel, A., Shenfine, A., Shenoy, S., Sherif, A., Shetty, N., Shetty, R., Sia, T. C., Sichimba, D., Siddique, H., Siddiqui, I., Simkens, G., Simoe, J., Simon, H., Sinan, L., Singh, T., Singh, K., Singh, Y., Sinha, L., Siragusa, L., Sluckin, T., Smart, Y. W., Smith, H., Smith, K., Smits, L., Sneep-van Kessel, C., Sohrabi, C., Solo´ rzano Pineda, O., Soma, A., Sooriyapiragasam, L., Søreide, K., Sparavigna, M., Spence, R., Spencer, N., Spiers, H., Spinelli, A., Sprakel, J., Sravanam, S., Srinivasan, M., Srinivasan, R., Staniszewska, A., Stanworth, S. J., Stasinos, K., Steele, R. J. C., Steinholt, I., Steinruecke, M., Stephen, B. -J., Stijns, J., Still, M., Stupalkowska, W., Subba, S., Subbotin, V. V., Sucharitkul, P., Sudarsanam, A., Sudhamsh Reddy, D., Suhardja, T., Suliman, M., Sund, M., Sunilkumar, A., Suresh, N., Sussmes, S., Sutton, P., Syltern, J., Taha, A., Takamizawa, Y., Takoutsing Dongmo, A. B., Tama´ s, T., Tan, L., Tan, J. L., Tan, K., Tan, E., Tan Yong Hui, A., Tanase, A., Tariverdiev, A., Tasnem, A., Tatar, C., Tay, E., Tejedor, P., Tesfaye, G., Tetinou, F., Thorpe, C., Thyø, A., Tlelo Amastal, D., Tolani, M., Tolga Saracoglu, K., To¨ lgyes, T., Tong, J., Torrent Jansa`, L., Toscano Igartua, S., Tovani Palone, M. R., Traff, H., Trevis, J., Tummers, W., Tur, A., Turchenko, I., Uche, V., Uddin, A., Udonsak, N., Ullah, M., Urbonas, T., Uwins, C., Uy Magadia, E., Uzair Qureshi, A., Uzun, K., Vadim, P., Valarche, G., Valdez Gonzalez, R. A., Vallee, M., van Beek, D. -J., van Dalen, A. S., van den Hondel, D., van der stok, E., van Dorp, M., van Oostendorp, S., van Praag, E., van Rees, J., van Silfhout, L., Varga, Z., Varghese, S., Varghese, C., Varghese, J., Vasilica, A. -M., Va´ squez Ojeda, X., Vega, E., Vehler, S., Venchiarutti, R., Vengatesan, S., Venn, M., Verma, D., Vianey Partida Nava, G., Victoria, D., Vieira, P., Vilar Alvarez, M. E., Vinci, D., Viscasillas Palla` s, G., Viswanath, M., Vivanco, J., Vizcaya Rodrı´guez, V., Vo, J., Volchanski, D., Voron, T., Voronovskyi, Y., Vu, J., Wadhwa, M., Wadhwa, S., Wagner, G., Wallace, M., Wang, Y. Y., Wang, J., Wani, A., Wanigasooriya, K., Wanjara, S., Wanjiku, N., Warner, C., Wei Leow, T., Weiser, T., Weisters, M., Wellington, M. J., Wells, C., Wenzelberg, C., Wettstein, D., Wezel, A., Wheldon, L., Widmer, L., Wilson, M., Wigmore, S., Wijayaratne, T., Wijeyaratne, M., 1176 | BJS, B. P. L., 108, Vol., 10 Sá-Marta, No., Sadien, I., Safarinteranya, D., Sagoo, K., Sakata, S., Saladino, E., Saleem, A., Saleem, S., Salehi, M., Salih, S., Sallinen, V., Salvans, S., Sam, Z. H., Samadov, E., Sampaio Alves, M., Sanad, A., Sánchez Wijnhoven, S., Wilkin, R., Williams, E., Willis, F., Winter, D., Wirsik, M. M., Wishah, B., Wong, G., Wong, W. J., Wong, K., Wong, K. -Y., Worku, D., Wright, E., Wright, J., Wroe Wright, O., Xenacki, S., Xia, W., Xu, W., Xu, Z., Yalcinkaya, A., Yang, W., Yang, P. -C., Yanishev, A., Yanzon de la Torre, A., Yao, H., Yaqoob, E., Yen Ling Quake, S., Yeo, D., Yeom, B., Yershov, D., Yiasemidou, M., Yildiz, A., Yiu, A., Yoav, M., Yong, E., Yoshimura, R., Younis, M. U., Younis Ringshawl, Z., Youssef, M., Yue, Y., Yuen, S., Yuldashev, R., Yurttas, C., Yves, B., Zaborowski, A., Zackeri, R., Zafar, A., Zahra, W., Zaidi, A., Zainudin, S., Zakeri, R., Zamora, I., Zamora, A. T., Zawistowski, M., Zbikowska, G., Zegers, W., Zehra, S., Zeyra, A., Zhagniyev, Z., Zhukova, L. G., Zivanovic, M., Zmuc, J., Zope, M., Zubayraeva, A., Zucker., B., Abahuje, E, Abbas, A, Abd El Aziz Abd El Maksoud, M, Abdelhady, A, Abdelhamid, S, Abdelkarem Ahmed Faraj, H, Abdelqader, B, Abdelrahman, T, Abdou, H, Abdullah, A, Abedua Harrison, M, Abem Owusu, E, Aboalazayem, A, Aboulhosn, R, Abu Oda, S, Abubakar, A, Abutaka, A, Acevedo Fontalvo, D, Acuna, S, Adefemi, A, Adegbola, S, Adenuga, T, Adeyeye, A, Adil Hilmi, A, Adisa, A, Aditya, K, Adjeso, T, Aftab, R, Afzal, A, Aggarwal, V, Aggarwal, A, Aguilera, R, Aguilera-Arevalo, M, Aguirre Salamanca, E, Aguirre-Allende, I, Ahari, D, Ahmad, H, Ahmad Rauf, F, Ahmad Zartasht Khan, A, Ahmed, S, Ahmed Fieturi, N, Ahmed Mohamed, S, Ahmed-Bakhsh, Z, Ahsan Javed, M, Akano, L, Akbar, A, Akhbari, M, Akhmedov, P, Aksit, G, Akula, Y, Alagaratnam, A, Al Majid, S, Al Mukhtar, O, Al Omran, H, Alasali, N, Al-Azzawi, M, Al-Habsi, R, Al-Iraqi, H, Al-Naggar, H, Alameer, E, Albirnawi, H, Alderson, D, Aldulaijan, F, Alejandro Miranda Ojeda, R, Alhasan, A, Ali, S, Ali, A, Ali Khan, M, Alimova, Y, Aljanadi, F, Aljubure, R, Allopi, N, Almedbal, H, Almubarak, M, Alqaidoom, Z, Alselaim, N, Alshaar, M, Alshammari, R, Altaf, K, Altiner, S, Altunpak, B, Alvarez Lozada, L, Amal Nahal, E, Amer, A, Amin, K, Aminu, U, Amisi Numbi, N, Amjad, T, Amoah, R, An, Y, Anastasopoulos, N, Andres Urrutia, J, Angarita, F, Angarita, K, Angel Freiria Eiras, M, Antypas, A, Anwar, M, Anwar, H, Apampa, T, Apostolou, K, Aquina, C, Arachchige Adithi Himika Randeni, R, Archila Godinez, M, Arez, O, Arezzo, A, Armonis, P, Arshad, S, Arshad Salman, M, Arshid, A, Arteaga Asensio, P, Arthur, T, Arumuga Jothi, A, Aryo Damara, F, Asensio Gomez, L, Ashcroft, J, Ashraf, S, Asif, A, Atif, M, Attaullah Khan, M, Avellaneda, N, Awad, S, Awadh, M, Axiaq, A, Ayad Mohammed Shuwayyah, A, Ayalew, D, Aytac, E, Azam, F, Azevedo, J, Azhar, B, Aziz, J, Aziz, A, Azzam, A, Baba Ndajiwo, A, Baig, M, Baker, D, Bakko, F, Balachandran, R, Balachandran, G, Balagizi Mudekereza, J, Balai, E, Balci, B, Balduzzi, A, Balhareth, A, Bandyopadhyay, S, Banerjee, D, Bangalore Mahalinga, D, Bankhead-Kendall, B, Bankole, N, Banwell, V, Baris Bengur, F, Baris Ozmen, B, Barnard, M, Barnett, R, Barreras Espinoza, J, Barrios, A, Bass, G, Bass, M, Bausys, A, Bavikatte, A, Bayram, J, Belousov, M, Berardi, A, Beamish, A, Beattie, C, Belia, F, Bellato, V, Bellikatti, S, Benjamens, S, Benlice, C, Bennedsgaard, S, Bennett, S, Bentounsi, Z, Bergenfeldt, H, Bergenfelz, A, Besselink, M, Bhandoria, G, Bhangu, E, Bhatia, M, Bhatti, M, Bilgili, Z, Bislenghi, G, Bisset, C, Biswas, S, Blake, J, Blanco, R, Boccalatte, L, Boden, R, Bojanic, C, Boland, M, Boland, P, Bollen, E, Bonci, E, Boni, L, Booth, A, Booth, R, Borakati, A, Borunda Escudero, G, Bosco, S, Bostrom, P, Botelho De Alencar Ferreira Cruz, P, Bouchagier, K, Bouhuwaish, A, Boutros, M, Boyce, K, Boyle, C, Bradshaw, L, Brandl, A, Brar, A, Brat, G, Brenkman, H, Brennan, C, Brines, C, Brookmyre, A, Brosnan, C, Brouwers, L, Brown, A, Brown, L, Brown, C, Brown, J, Bs, V, Buksh, M, Bunani Emmanuel, M, Burbano, D, Burelli, A, Burke, A, Burke, J, Burlov, N, Burns, A, Burton, O, Butt, A, Buzra Ozkan, B, Cabrera Silva, L, Caicedo, E, Calderbank, T, Cambridge, W, Campelo, G, Can Tatar, O, Carbone, F, Carrano, F, Casallas, D, Casanova Portoles, D, Casciani, F, Cassimjee, I, Castaneda Ramirez, O, Catalan, V, Caviedes, J, Cayetano, L, Ceresoli, M, Chan, M, Chan, V, Chandrasinghe, P, Chapman, S, Chaturvedi, A, Chaudhry, D, Chaudry, H, Chen, H, Cheng, A, Chernykh, M, Cherrie, A, Cheruiyot, I, Cheung, J, Chia, C, Chica, J, Chinai, N, Chirwa, A, Chiwaligo, J, Choi, A, Choi, J, Chowdhury, M, Christopher, E, Christou, N, Chu, T, Chua, D, Chua, H, Chung, C, Cihat Yildirim, A, Cillo, M, Cioffi, S, Claireaux, H, Clermonts, S, Clifford, R, Climent, M, Clynch, A, Coelen, R, Colas-Ruiz, E, Collar, A, Collard, M, Conlon, K, Connelly, T, Connor, K, Cook, J, Correia De Sa, T, Cosgun Acar, N, Costa, T, Couch, D, Cowper, S, Creavin, B, Crook, B, Curell, A, D'Alessio, R, Dale, J, Damgaard Eriksen, J, Dario Martin Gonzalez, I, Darwish, A, Das, M, Das, R, Das, K, Dave, R, David, S, Davies, T, Davis, C, Davison, S, Davletshina, V, Dawidziuk, A, Dawson, A, De Andres Crespo, M, De Berker, H, De Dieu Ngo, P, Dekker, E, De La Caridad Espinosa Luis, R, De Lacy, B, Demartines, N, De Montserrat Medina Sifuentes, A, De Silva, S, Del Rio, C, Delaune, V, Dell, A, Demirbas, I, Demirli Atici, S, Deniz Tepe, M, Derebey, M, Desai, G, Desai, M, Devarakonda, S, Deveras, N, Di Franco, G, Di Martino, M, Di Marzo, F, Diaz, A, Diaz Del Gobbo, G, Diazcastrillon, C, Dick, L, Dickinson, K, Diego, E, Dimasi, I, Ding, A, Dingemans, S, Dixon, L, Dixon, B, Doherty, W, Dooreemeah, D, Donohue, C, Dornseifer, M, Dossa, F, Dossou, W, Drake, T, Drami, I, Drevin, G, Du Plessis, M, Dudi-Venkata, N, Dudley, R, Duffy, S, Duklas, D, Dumbrava, B, Duygu Avlar, F, Dworzynska, A, Ebrahim, W, Ebrahim, A, Efren Lozada Hernandez, E, Ehigie, N, El Boghdady, M, El Hasnaoui, C, El Sheikh, M, El-Hussuna, A, Eldurssi, O, Elfeki, H, Elhadi, M, Elhassan, M, Elhissi, A, Elliot, B, Elsenbroek, C, Elsolh, B, Elson, N, Eltyeb, H, Emerson, H, Emile, S, Endalle, G, English, W, Ercisli, C, Espinosa, G, Essam Abdelraheem, M, Essangri, H, Etienne, P, Evans, M, Evans, T, Ezeme, C, Ezzahraa, F, Fadalla, T, Fagan, J, Fahmy, M, Fairfield, C, Falade, O, Famularo, S, Faqar-Uz-Zaman, F, Farid, Y, Farooq, A, Farooq, H, Farooqui, F, Farquharson, B, Faruqi, A, Faulder, R, Faut, M, Fechner, K, Feenstra, T, Fehervari, M, Fernandez, L, Fernandez Alberti, J, Ferrario, L, Field, D, Fiore, L, Fingerhut, S, Finlayson, S, Fleming, N, Fleming, C, Florial, E, Fok, M, Fokin, D, Foley, M, Forero, M, Forgan, T, Fornasiero, M, Fowler, H, Fowler, G, Franchi, E, Franklin, L, Fredriksson, A, Fruhling, P, Fuentes Navarrette, G, Fulop, A, Furtado, M, Gaarder, T, Galbraith, N, Gallagher, I, Gallo, G, Gana, T, Gaskin, E, Gasparini, M, Gatan, R, Geary, E, Gelaye Wudineh, K, Gemenetzis, G, Georgi, M, Ghalige, H, Ghareeb, W, Ghatwary Tantawy, T, Ghomsi, C, Ghuman, A, Giannakis, P, Giron, F, Gjengedal, K, Gkotsis, E, Glasbey, J, Godahewa, S, Godula, D, Goffredo, P, Goh, S, Golriz, M, Gomez, L, Gomez Gomez, D, Gonzalez, R, Gonzalez, D, Gonzalez Gutierrez, E, Gopar, D, Gordini, L, Gori, A, Gortazar, S, Gousy, N, Gowda, R, Gowda, M, Gqada, J, Grechenig, M, Greer, J, Gregorio, L, Grigorova, A, Grimes, H, Groot, V, Grossman, R, Gruber, R, Gruter, A, Guest, R, Gujjuri, R, Gulcek, E, Gulcu, B, Gull, K, Gulmez, M, Gupta, V, Gutlic, A, Guven, T, Gwatirisa, T, Gwini, G, Gwodog, P, Gysling, S, Habib, M, Hafeez Bhatti, A, Hallesmith, J, Halloran, S, Hamza Sadiq, M, Haney, C, Hanna, N, Hanna, L, Hannington, M, Harbjerg, J, Haribaskaran, D, Harran, N, Harrington, B, Harrison, E, Hasan, R, Hashmi, S, Hassan, M, Hassan, A, Haverkamp, L, Hazen, S, Heer, B, Heil, J, Helliwell, J, Henriksen, N, Henshall, D, Hermanson, M, Hermena, S, Hettiarachchi, D, Hextall, C, Hidalgo, M, Hidayat, H, Hider, A, Higgins, P, Hinchliffe, R, Hirani, D, Hirpara, D, Hisham, I, Hite, M, Hoh, S, Holmberg, C, Holmich, E, Holst, F, Hossam, A, Hossam Elfallal, A, Howard, P, Huaman, E, Huang, Y, Huang, L, Huang, D, Huber, T, Hugh, J, Hughes, J, Huttner, F, Huynh, R, Hylands, A, Iannuzzi, J, Ielpo, B, Iftikhar Talib, A, Ignacio, J, Ignatavicius, P, Ike, S, Ikwu, C, Inama, M, Ing, A, Ingels, A, Isik, A, Islam, N, Ives, I, Al-Hasan, A, Perez Rivera, C, Jacome, F, Jaffer, T, Jagiella-Lodise, O, Jain, M, Jain, K, Jakubauskas, M, Jalal, M, James, H, Jang, Y, Janssen, B, Jansson, H, Jariod-Ferrer, U, Javanmard, H, Javed, S, Jayarajah, U, Jayasuriya, I, Je, J, Jessop, Z, Jia Lin Tang, E, Jiang, H, Jiayan, Y, Jih Huei, T, Jimenez-Rodriguez, R, Joh, D, Johnson, A, Jones, N, Jones, C, Jordan, C, Jose Nunez Ju, J, Jose Pizarro, M, Jose Salazar, C, Joseph, J, Justiniano, C, Kabir, T, Kadhum, M, Kalfountzos, C, Kalogiannaki, E, Kalyanasundaram, K, Kamarajah, S, Kamil Quraishi, M, Kanemitsu, Y, Kapila, A, Kapila, V, Karagiannidis, G, Kashif, M, Kathiravelupillai, S, Kathiravelupillai, A, Katsogridakis, E, Kaur, K, Kaur Sekhon Inderjit Singh, H, Kausur, N, Kawka, M, Keehan, G, Kehlet Watt, S, Kelly, M, Kelvin Egbuchulem, I, Kembuan, G, Khajeh, E, Khaled Elfaitur, A, Khan, M, Khan, S, Khan, D, Khan, H, Khatkar, H, Khatkov, E, Khaw, R, Kim, B, Kishore Siddiraju, K, Kitua, D, Kirimtay, B, Kmezic, S, Knight, S, Koeter, T, Koh, A, Koh Hong Xiang, F, Kojo Anyomih, T, Kok, A, Kokelaar, R, Koliarakis, I, Kolli, S, Kong, J, Konig, D, Koshy, M, Kotze, P, Kourdouli, A, Kowal, M, Kraima, A, Kramer, F, Kryzauskas, M, Kuchynskyi, I, Kuemmerli, C, Kuiper, S, Kumar, S, Kumar, A, Kumar, L, Kumar, H, Kumar, N, Kumar Bandyopadhyay, S, Kumar Garg, P, Kumar Venkatappa, S, Kung, J, Kural, S, Kushairi, A, Kuuzie, E, Kvietkauskas, M, Kwek, I, La, J, Lai, L, Lakpriya, S, Lam, K, Lami, M, Lansdorp-Vogelaar, I, Lapolla, P, Larsen, H, Latif, J, Laudari, U, Laurnezi, A, Lawal, A, Lawday, S, Lederhuber, H, Lednev, A, Lee, R, Van Leerdam, M, Lefevbre, G, Lesmus, M, Leyva Moraga, F, Leyva Moraga, E, Li, H, Li, A, Li, Z, Licardie, E, Light, A, Lightner, A, Lin, A, Lincango, E, Litta, F, Liu, H, Lofthouse, B, Londono, M, Lopes, R, Lopes De Freitas, R, Lopez, L, Lopez, A, Lopez-Gomez, J, Lopez-Pena, G, Lowe, R, Lowe, D, Lowey, M, Loy, G, Lozanovski, V, Luzon, J, Lynn, P, Maccabe, T, Machielsen, A, Mafla Herreria, C, Maggino, L, Mahawar, K, Mahmood, D, Mahmoud, M, Mahtani, K, Maitra, I, Maji, S, Majiet, I, Mal, L, Malherbe, J, Malhotra, K, Malkomes, P, Man, E, Manan Sheikh, A, Manjunath, S, Manzano Nunez, R, Manzoor, S, Maqsood, R, Marchegiani, G, Marchegiani, F, Marin, D, Marin, A, Marks, I, Marson, E, Martensen, A, Martin, D, Martin Martin, G, Martin-Perez, B, Martinez, P, Marwaha, P, Mashauri, C, Mashbari, H, Masior, L, Masri, R, Masud, L, Masudi, S, Mateu Calabuig, G, Math, S, Matrachisia, A, Mayol, J, Mazingi, D, Mazzotta, A, Mcalinden, J, Mccabe, G, Mccolm, L, Mcelvaney, H, Mcgivern, K, Mcgovern, J, Mcguinness, E, Mcinerney, N, Mckay, S, Mckee, C, Mckenna, M, Mckenna, N, Mclean, K, Mediratta, S, Medkova, Y, Medzhidov, O, Mehraj, A, Mekhael, M, Mekinde, O, Mellenthin, C, Melucci, A, Mentor, K, Merchant, J, Messias, H, Messeha, M, Meza, C, Mhango, P, Miladinov, M, Milagros Niquen Jimenez, M, Miller, P, Mills, E, Milton, A, Minayeva, O, MinHua Zheng, Z, Mischlinger, H, Mockli, B, Modi, R, Mohamed, H, Mohamed, M, Mohamed Abulghasm, T, Mohammad, S, Mohammed, T, Mohammed, A, Mohan, H, Mohan, M, Moin, I, Mok, V, Molina, G, Moloney, J, Moneim, J, Monfort Mira, M, Montcusi Ventura, B, Montouri, M, Moossdorff, M, Mora-Guzman, I, Moran, B, Moran, R, Moreno-Ordaz, S, Morera, A, Morgan, R, Morley, R, Moro-Valdezate, D, Moros, S, Moss, J, Morven, A, Morton, D, Moynihan, A, Moyon, M, Muduli, N, Mugla, N, Mugla, W, Muller, P, Mun, G, Mundhada, R, Munir, I, Munoz, F, Munoz, E, Munoz, A, Munoz Balderas, D, Murgitroyd, E, Murray, V, Murthy, S, Mushiwokufa, W, Mustafa, H, Mustakimov, B, Mutambanengwe, P, Myint, P, Nadkarni, S, Naess, P, Nahar, S, Naidoo, P, Nam, R, Nandhra, S, Nanjappa, N, Narasimhan, V, Nardi, W, Nasir, M, Naughton, A, Naumann, D, Navarro, S, Nawaaz Karimbocus, M, Nazir, A, Ndereya, S, Ndong, A, Negoi, I, Nel, D, Nelson, D, Nepal, S, Nugent, T, Nepogodiev, D, Neufeld, J, Ng, J, Ng, D, Ng, C, Ngaserin, S, Ngu, L, Ngwenya, E, Fhearaigh, R, Nikolousakis, T, Ninkovic, M, Nita, G, Nitschke, C, Noren, E, Noton, T, Novikova, A, Nowinka, Z, Nyakunengwa, T, Nyalundja, A, Nzenwa, I, Kristensen, H, O'Brien, C, O'Brien, L, O'Brien, S, O'Reilly, J, O'Rourke, S, O'Sullivan, M, O'Dwyer, M, Ochieng, L, Oderoha, E, Oh, K, Ohlberger, L, Olcum, M, Olkina, A, Omkumar, M, Omnitel, B, Oncel Yakar, D, Ong, K, Ong Wei Lin, L, Ooi, R, Ooi, S, Oomman, A, Oon Tyjet, D, Opiyo, S, Oscullo Yepez, J, Osei-Kuffour, N, Osunronbi, T, Ottlakan, A, Oussama Kacimi, S, Ovaere, S, Ozair, A, Pachler, F, Pai Oo, S, Paiella, S, Panaiotti, L, Panda, N, Pandarinath, S, Pandey, D, Pandrowala, S, Papa Mamadou, F, Paranathala, M, Park, J, Parmar, C, Parvez, A, Pasovic, L, Pasquer, A, Pasumarthy, N, Pata, F, Patel, T, Patel, P, Patel, N, Patel, M, Patron Uriburu, N, Patrone, R, Paul, A, Pavan Kumar, O, Pavithran, A, Pedraza Ciro, M, Pellino, G, Peloso, A, Pena Gallardo, M, Pena Velazquez, A, Perea, J, Perez-Sanchez, L, Perra, T, Perrotta, G, Petersson, P, Petra, G, Petrucciani, N, Pickin, C, Pino, V, Pinotti, E, Pinto, F, Plum, P, Podesta, F, Pollini, T, Pompeu Sa, M, Ponce Leon, F, Ponniah, H, Ponte De Sousa, X, Ponton, J, Pontula, A, Popa, M, Portilla, A, Posner, F, Post, S, Potolicchio, A, Pouwels, S, Povo, A, Prasad, P, Preciado, S, Preece, R, Proud, D, Pulido Segura, J, Puliyath, N, Qui, M, Quimbaya Rodriguez, A, Raby-Smith, W, Racovita, A, Rad, A, Radwan, R, Rafaih Iqbal, M, Rafik, A, Raguan, B, Rahi, M, Rahiri, J, Rahme, J, Rai, L, Raj, A, Raj Saksena, A, Raja, M, Ramirez, J, Ramzi, J, Ranstam, J, Rao, C, Rashid, A, Ratnayake, B, Rattanasirivilai, K, Raubenheimer, K, Ravikumar, N, Ravn, S, Razoz, N, Rea, W, Regan, A, Rela, M, Remme, A, Rey Chaves, C, Reyes, A, Riad, A, Rice, D, Rios Quintana, K, Ritter, A, Roalso, M, Robinson, D, Rodriguez, J, Rodriguez, F, Rodriguez, M, Rogers, A, Rohila, J, Romanyuc, D, Romic, I, Rommaneh, M, Rompianesi, G, Rosa, F, Roscio, F, Rose, A, Rotimi, T, Ruiz, H, Ruiz Yucuma, J, Ruiz-Ucar, E, Ruslan, M, Rutegard, M, Ryan Harper, E, Ryckx, A, Rydbeck, D, Sa-Marta, E, Sadien, I, Safari Nteranya, D, Sagoo, K, Sakata, S, Saladino, E, Saleem, A, Saleem, S, Salehi, M, Salih, S, Sallinen, V, Salvans, S, Sam, Z, Samadov, E, Sampaio Alves, M, Sanad, A, Sanchez Fonseca, S, Sanchez Teran, A, Sanchez Ussa, S, Sandli, O, Sanfey, H, Sanghera, J, Sani, I, Santafe Guerrero, M, Sante Fornasiero, M, Santes Jasso, O, Santos Pereira, I, Santos Sousa, H, Saratzis, A, Sarmiento Alarcon, A, Saumtally, T, Sayyed, R, Schettino, M, Schleimer, L, Schmidt, T, Schondffelt, K, Schwab, M, Scott, A, Searle, H, Sebopelo, L, Seeglier, B, Seishima, R, Semenvov, D, Senent-Boza, A, Sepulveda, J, Serenari, M, Serrano Navidad, M, Sert, I, Sewart, E, Sgro, A, Shadrina, V, Shah, K, Shahid, F, Shalaby, M, Shankar, B, Shapiro, J, Sharma, L, Sheel, A, Shenfine, A, Shenoy, S, Sherif, A, Shetty, N, Shetty, R, Sia, T, Sichimba, D, Siddique, H, Siddiqui, I, Simkens, G, Simoe, J, Simon, H, Sinan, L, Singh, T, Singh, K, Singh, Y, Sinha, L, Siragusa, L, Sluckin, T, Smart, Y, Smith, H, Smith, K, Smits, L, Sneep-Van Kessel, C, Sohrabi, C, Solorzano Pineda, O, Soma, A, Sooriyapiragasam, L, Soreide, K, Sparavigna, M, Spence, R, Spencer, N, Spiers, H, Spinelli, A, Sprakel, J, Sravanam, S, Srinivasan, M, Srinivasan, R, Staniszewska, A, Stanworth, S, Stasinos, K, Steele, R, Steinholt, I, Steinruecke, M, Stephen, B, Stijns, J, Still, M, Stupalkowska, W, Subba, S, Subbotin, V, Sucharitkul, P, Sudarsanam, A, Sudhamsh Reddy, D, Suhardja, T, Suliman, M, Sund, M, Sunilkumar, A, Suresh, N, Sussmes, S, Sutton, P, Syltern, J, Taha, A, Takamizawa, Y, Takoutsing Dongmo, A, Tamas, T, Tan, L, Tan, J, Tan, K, Tan, E, Tan Yong Hui, A, Tanase, A, Tariverdiev, A, Tasnem, A, Tatar, C, Tay, E, Tejedor, P, Tesfaye, G, Tetinou, F, Thorpe, C, Thyo, A, Tlelo Amastal, D, Tolani, M, Tolga Saracoglu, K, Tolgyes, T, Tong, J, Torrent Jansa, L, Toscano Igartua, S, Tovani Palone, M, Traff, H, Trevis, J, Tummers, W, Tur, A, Turchenko, I, Uche, V, Uddin, A, Udonsak, N, Ullah, M, Urbonas, T, Uwins, C, Uy Magadia, E, Uzair Qureshi, A, Uzun, K, Vadim, P, Valarche, G, Valdez Gonzalez, R, Vallee, M, Van Beek, D, Van Dalen, A, Van Den Hondel, D, Van Der Stok, E, Van Dorp, M, Van Oostendorp, S, Van Praag, E, Van Rees, J, Van Silfhout, L, Varga, Z, Varghese, S, Varghese, C, Varghese, J, Vasilica, A, Vasquez Ojeda, X, Vega, E, Vehler, S, Venchiarutti, R, Vengatesan, S, Venn, M, Verma, D, Vianey Partida Nava, G, Victoria, D, Vieira, P, Vilar Alvarez, M, Vinci, D, Viscasillas Pallas, G, Viswanath, M, Vivanco, J, Vizcaya Rodriguez, V, Vo, J, Volchanski, D, Voron, T, Voronovskyi, Y, Vu, J, Wadhwa, M, Wadhwa, S, Wagner, G, Wallace, M, Wang, Y, Wang, J, Wani, A, Wanigasooriya, K, Wanjara, S, Wanjiku, N, Warner, C, Wei Leow, T, Weiser, T, Weisters, M, Wellington, M, Wells, C, Wenzelberg, C, Wettstein, D, Wezel, A, Wheldon, L, Widmer, L, Wilson, M, Wigmore, S, Wijayaratne, T, Wijeyaratne, M, Wijnhoven, B, Wilkin, R, Williams, E, Willis, F, Winter, D, Wirsik, M, Wishah, B, Wong, G, Wong, W, Wong, K, Worku, D, Wright, E, Wright, J, Wroe Wright, O, Xenacki, S, Xia, W, Xu, W, Xu, Z, Yalcinkaya, A, Yang, W, Yang, P, Yanishev, A, Yanzon De La Torre, A, Yao, H, Yaqoob, E, Yen Ling Quake, S, Yeo, D, Yeom, B, Yershov, D, Yiasemidou, M, Yildiz, A, Yiu, A, Yoav, M, Yong, E, Yoshimura, R, Younis, M, Younis Ringshawl, Z, Youssef, M, Yue, Y, Yuen, S, Yuldashev, R, Yurttas, C, Yves, B, Zaborowski, A, Zackeri, R, Zafar, A, Zahra, W, Zaidi, A, Zainudin, S, Zakeri, R, Zamora, I, Zamora, A, Zawistowski, M, Zbikowska, G, Zegers, W, Zehra, S, Zeyra, A, Zhagniyev, Z, Zhukova, L, Zivanovic, M, Zmuc, J, Zope, M, Zubayraeva, A, Zucker, B, Aguilera-Arévalo, M -L, Aguirre Salamanca, E J, Al-Asali, N, Altıner, S, Alvarez Lozada, L A, Anastasopoulos, N -A, Andrés Urrutia, J, Angarita, K -L, Ángel FreirÍa Eiras, M, Anwar, M A, Apampa, T O, Archila Godínez, M I, Arteaga Asensio, P C, Bankole, N D A, Barreras Espinoza, J A, Bhatti, M T, Bonci, E -A, Borunda Escudero, G E, Bosco, S J, Boström, P, Botelho de Alencar Ferreira Cruz, P, Caicedo, E Y, Castañeda Ramírez, O A, Catalán, V, Chen, H W, Chowdhury, M R, Chua, H W, Coelen, R -J, Colás-Ruiz, E, Correia de Sá, T, Coşgun Acar, N, D’Alessio, R, David, S O, de Andres Crespo, M, de Berker, H, de Dieu Ngo, P, de la Caridad Espinosa Luis, R, de Lacy, B, de Montserrat Medina Sifuentes, A, del Rio, C, Demirbaş, I, Díaz, Á, Diaz del Gobbo, G, Diaz-Castrillon, C, du Plessis, M C, Dumbrava, B -D, Efrén Lozada Hernández, E, Fernández Alberti, J, Forero, M P, Fredriksson, Å, Fülöp, A, Gatan, R G, Gortázar, S, Gregório, L, Grüter, A, Gülçek, E, Hafeez Bhatti, A B, Hoh, S M, Hölmich, E, Hüttner, F, Alhasan, A J M S, Perez Rivera, C J, Jácome, F, Jariod-Ferrer, Ú, José, J, José Núñez Ju, J, José Pizarro, M, Khan, M F, Kırımtay, B, Kmezić, S, Koëter, T, König, D, Leyva Moraga, F A, Li, H L, Londoño, M A, Lopes de Freitas, R, López, A I, Mafla Herrería, C A, Manzano Nuñez, R, Marín, D, Martín Martín, G, Masior, Ł, Möckli, B, Mohamed, H M, Mohammad, S A, Mohammed, T O, Montcusí Ventura, B, Mora-Guzmán, I, Morán, R A R, Morera, Á, Moss, J -L, Moyón, M, Müller, P, Muñoz, F, Muñoz, E, Muñoz, A, Muñoz Balderas, D C, Ng, C E, Fhearaigh, R N, Nikolousakis, T -K, Kristensen, H Ø, O’Brien, L, O’Brien, S, O’Reilly, J, O’Rourke, S, O’Sullivan, M, O’Dwyer, M, Oh, K E, Öhlberger, L, Ölçüm, M, Oscullo Yepez, J J, Osei-kuffour, N, Ottlakán, A, Pavan Kumar, O M, Peña Gallardo, M T, Peña Velazquez, A, Pérez-Sánchez, L E, Pompeu Sá, M, Ponniah, H S, Ponte de Sousa, X, Portilla, A L, Pulido Segura, J A, Quimbaya Rodríguez, A S, Racoviţă, A, Rahiri, J -L, Rey Chaves, C E, Roalsø, M, Rodríguez, F, Rodriguez, M C, Ruiz-Úcar, E, Rutegård, M, Sá-Marta, E, Sam, Z H, Emile, Sameh H, Sánchez Fonseca, S, Sgrò, A, Sia, T C, Smart, Y W, Sneep-van Kessel, C, Solórzano Pineda, O, Stephen, B -J, Takoutsing Dongmo, A B, Tamás, T, Tan, J L, Thyø, A, Tölgyes, T, Torrent Jansà, L, Tovani Palone, M R, Valdez Gonzalez, R A, van Beek, D -J, van Dalen, A S, van den Hondel, D, van der stok, E, van Dorp, M, van Oostendorp, S, van Praag, E, van Rees, J, van Silfhout, L, Vasilica, A -M, Vásquez Ojeda, X, Vilar Alvarez, M E, Viscasillas Pallàs, G, Vizcaya Rodríguez, V, Wang, Y Y, Wellington, M J, Wirsik, M M, Wong, W J, Wong, K -Y, Wright, O Wroe, Yang, P -C, Yanzon de la Torre, A, Younis, M U, Zamora, A T, and Surgery

Subjects
Adult, Male, medicine.medical_specialty, Biomedical Research, Coronavirus disease 2019 (COVID-19), International Cooperation, Practice Patterns, Commission, Global Health, Health Services Accessibility, Perioperative Care, Education, Surgeon, COVID-19, surgery, perioperative care, Medical, Pandemic, Humans, Medicine, Practice Patterns, Physicians', Graduate, Pandemics, Surgeons, Health Resource, Infection Control, Physicians', Surgical Procedures, business.industry, General surgery, Middle Aged, Operative, Education, Medical, Graduate, Surgical Procedures, Operative, Perioperative care, Health Resources, Surgery, Female, business, Human
Abstract

Background Coronavirus disease 2019 (COVID-19) was declared a pandemic by the WHO on 11 March 2020 and global surgical practice was compromised. This Commission aimed to document and reflect on the changes seen in the surgical environment during the pandemic, by reviewing colleagues’ experiences and published evidence. Methods In late 2020, BJS contacted colleagues across the global surgical community and asked them to describe how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had affected their practice. In addition to this, the Commission undertook a literature review on the impact of COVID-19 on surgery and perioperative care. A thematic analysis was performed to identify the issues most frequently encountered by the correspondents, as well as the solutions and ideas suggested to address them. Results BJS received communications for this Commission from leading clinicians and academics across a variety of surgical specialties in every inhabited continent. The responses from all over the world provided insights into multiple facets of surgical practice from a governmental level to individual clinical practice and training. Conclusion The COVID-19 pandemic has uncovered a variety of problems in healthcare systems, including negative impacts on surgical practice. Global surgical multidisciplinary teams are working collaboratively to address research questions about the future of surgery in the post-COVID-19 era. The COVID-19 pandemic is severely damaging surgical training. The establishment of a multidisciplinary ethics committee should be encouraged at all surgical oncology centres. Innovative leadership and collaboration is vital in the post-COVID-19 era.

Published
2021

13. THE MAIN PARAMETERS OF CELLULAR IMMUNITY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER: RELATIONSHIP WITH EFFICIENCY OF CHEMOTHERAPY

Author

L. G. Zhukova, E. K. Shoua, E. G. Slavina, M. A. Okruzhnova, N. Т. Dzhgamadze, Z. G. Kadagidze, V. A. Nurtdinova, A. I. Chertkova, and A. A. Borunova

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Cellular immunity, overall survival, medicine.medical_treatment, Immunology, chemotherapy, peripheral lymphocyte subpopulations, 03 medical and health sciences, disease progression, 0302 clinical medicine, Internal medicine, medicine, Immunology and Allergy, In patient, Triple-negative breast cancer, Chemotherapy, business.industry, RC581-607, 030104 developmental biology, triple negative breast cancer, 030220 oncology & carcinogenesis, Immunologic diseases. Allergy, business, progression-free survival
Abstract

Chemotherapy is among the primary methods of treating advanced breast cancer. It was shown that clinical efficacy of various chemotherapeutic agents in many cases depends not only on their direct cytostatic and/or cytotoxic effect upon tumor cells, but also on their ability to modulate phenotype of the tumor cells and to influence anti-tumor immune response. Initial state of the immune system and its response to treatment is crucial. Antitumor response involves cells of innate and adaptive immunity (NK, NKT, T cells). These populations are heterogeneous and contain, e.g., cells with antitumor activity and regulatory (suppressor) cells that suppress immune response and promote tumor progression. The aim of this work was to determine the relationship between the initial state of cellular immunity of patients suffering from locally advanced breast cancer with triple negative phenotype, and clinical effect of chemotherapy (cisplatin + doxorubicin/paclitaxel), and studying effects of the therapy upon subpopulation profiles of peripheral blood lymphocytes in the patients. We registered the terms of the disease progression as well as overall survival and progression-free survival. The disease progressed in 25 of 53 cases (47.2%) whereas 28 of 53 patients (52.8%) remained progression-free. The observation period was 35.5 months. Laboratory examination of the patients included immunophenotyping of peripheral blood lymphocytes and determination of NK cell cytotoxic activity before and after chemotherapy. Percentages of effectors and regulatory lymphocyte populations were determined. The results obtained showed that, for some lymphocyte subsets, the pre-treatment differences of cell percentage deviations from control were found between the progression-free groups and patients with progression of the disease. The differences in percentages of NKT cells and lymphocytes expressing CD25 activation marker proved to be most significant. Decreased number of NKT cells and activated CD25+ lymphocytes prior to chemotherapy was associated with increased probability of disease progression. Reduced percentage of NKT cells against control was observed in 56% of patients from the progression group (PD), and only 21.4% in the group free of disease progression (DF). [OR = 4.6 (95% CI 1.4 to 15.4)]. Percentage of CD25+ lymphocytes was decreased from 68.2% in the PD group, and 28.6% for DF patients [OR = 5.4 (95% CI 1.6-18.1)]. We studied relationships between the overall survival (OS) and percentage of perforin-containing NK, NKT, and T cells, and mean perforin fluorescence density (PFD) in these lymphocyte subsets in 26 of the 53 patients before treatment. A statistically significant positive correlation was revealed between OS and perforin PFD in all the three cell populations under study. Normalization of the parameters altered before treatment, and an increase of T cell numbers was observed in the disease-free patients.

Published
2018

14. METASTASIS OF RENAL CANCER TO BREAST: DESCRIPTION OF CLINICAL CASE

Author

E. V. Chernova, V. A. Khaylenko, L. G. Zhukova, A. G. Abdullaev, D. V. Komov, L. N. Lyubchenko, A. V. Khaylenkо, N. E. Kudashkin, and D. A. Burov

Subjects
medicine.medical_specialty, Urology, medicine.medical_treatment, renal cancer, metastasis in breast, Metastasis, Surgical removal, nephrectomy, medicine, Radiology, Nuclear Medicine and imaging, Surgical treatment, Chemotherapy, business.industry, Cancer, medicine.disease, Nephrectomy, medicine.anatomical_structure, Oncology, Nephrology, Medicine, Surgery, Radiology, Pancreas, business, Clear cell
Abstract

The main method of treatment of local stages of clear cell renal cancer is surgical. The question of conducting adjuvant irradiation and chemotherapy after radical operations is open. Patients with solitary distant metastases and a favorable prognosis may become candidates for surgical treatment. Surgical removal of isolated solitary metastases allows to achieve 35–60 % of 5-year overall survival. The patient, observed in N.N. Blokhin National Medical Research Center of Oncology with metastasis of renal cancer in the pancreas, and then in the breast is an extremely rare clinical case presented in this article.

Published
2018

15. The prospects for cisplatin and nab-paclitaxel combination therapy in patients with pre-treated triple-negative breast cancer. Description of the clinical case

Author

E. V. Lubennikova, L. G. Zhukova, I. R. Suslova, and K. S. Bardovskaya

Subjects
Cisplatin, Oncology, medicine.medical_specialty, Combination therapy, business.industry, General Medicine, taxanes, nab-paclitaxel, triple negative breast cancer, Internal medicine, medicine, Medicine, In patient, Clinical case, business, Triple-negative breast cancer, Nab-paclitaxel, medicine.drug
Abstract

Molecular and biological features of triple negative breast cancer (TN BC) determine the limited possibilities of systemic therapy and, as a consequence, the more aggressive course of the disease. Taxanes are one of the most effective chemotherapies used in breast cancer therapy. The special form of paclitaxel nab-paclitaxel makes it possible to obtain an objective and a subjective effect, which is especially important in the pre-treated patients. In addition, the drug has a favourable safety profile and a well-controlled toxicity.The article contains a review of the literature on the prospects for the use of nab-paclitaxel in breast cancer, especially in its triple negative version, and a description of the clinical case of therapy with a combination of cisplatin and nab-paclitaxel in a young patient with BRCA-1-associated TN breastcancer.

Published
2018

16. The use of regorafenib in patients with disseminated gastrointestinal stromal tumours. A review of the literature. A clinical case

Author

D. A. Filonenko, S. V. Petukhova, E. I. Khatkova, K. A. Vorontsova, E. I. Chichikov, B. M. Medvedeva, and L. G. Zhukova

Subjects
stromal tumours of the gastrointestinal tract, Oncology, medicine.medical_specialty, multikinase inhibitors, GiST, Sunitinib, business.industry, Imatinib, General Medicine, Disease, Gene mutation, medicine.disease, chemistry.chemical_compound, chemistry, Internal medicine, Regorafenib, medicine, regoraphanib, Medicine, Disseminated disease, business, neoplasms, Tyrosine kinase, medicine.drug
Abstract

The survival of patients even with disseminated disease reached 7–8 years after introduction of imatinib and sunitinib for the treatment of gastrointestinal stromal tumours (GIST) into everyday clinical practice. These drugs efficacy is largely determined by the presence and any mutations of C-KIT and PDGFR genes. It was established that new mutations appear in most tumours against the background of tyrosine kinase inhibitors therapy, which causes the development of secondary resistance and the progression of the disease in most cases. The search for opportunities to overcome the newly developed or initially existing resistance caused by different gene mutations continues to be of vital importance. One of such drugs is regorafenib, which has demonstrated antitumour activity against progression on imatinib and/or sunitinib. The paper reviews the studies of the efficacy of regoraphanib in patients with disseminated GIST, taking into account the presence and any mutations of C-KIT and PDGFR genes, and presents a description of their own clinical case of prolonged use of the drug in a patient who have received earlier both imatinib and sunitinib.

Published
2018

17. Results of the use of ramucirumab in combination with paclitaxel or ramucirumab monotherapy as the second line treatment in patients with disseminated HER2-negative gastric or cardioesophageal junction adenocarcinoma: experience of N.N. Blokhin russian cancer research center of the ministry of health of Russia

Author

N. S. Besova, T. A. Titova, E. V. Trusilova, V. A. Gorbunova, A. A. Tryakin, O. O. Gordeeva, A. A. Rumyantsev, R. Yu. Nasyrova, L. G. Zhukova, A. V. Snegovoy, E. V. Artamonova, L. V. Manzyuk, and A. A. Fedenko

Subjects
Oncology, Chemotherapy, medicine.medical_specialty, Second line treatment, ramucirumab, business.industry, medicine.medical_treatment, second line treatment, General Medicine, Gastroesophageal Junction Adenocarcinoma, Second line chemotherapy, Ramucirumab, paclitaxel, Safety profile, Gastric adenocarcinoma, Internal medicine, Combination group, Medicine, business, advanced gastric cancer
Abstract

Background.Working out of the second line chemotherapy of advanced gastric adenocarcinoma is a promising approach to cancer therapy. Ramucirumab, an anti-angiogenic agent specifically targeting vascular endothelial growth factor receptor-2 (VEGFR-2). In April 2014, the FDA approved ramucirumab as a single agent or in combination with paclitaxel for treatment of advanced gastric or gastroesophageal junction adenocarcinoma that has progressed on or after prior fluoropyrimidineor platinum containing chemotherapy based on data of REGARD and RAINBOW trials.Materials and Methods: From June 2016 to 15Jan 201837 pts with advanced GC were treated with ramucirumabin the second line treatment as single agent (11 pts) or in combination with paclitaxel (26 pts) in N.N.Blokhin National medical research center of oncology.Results: edian PFS (MPFS) and median OS (MOS) was 1,8 and 7,6 mons for monotherapy group. For combination group MPFS was 4,0mons, MOS -10,6 mons. Ramucirumab had an acceptable safety profileConclusions:ur data are similar to the data of international randomized trials.

Published
2018

18. Ribociclib in 1st line HR+ breast cancer treatment

Author

L G Zhukova, Olga O. Gordeeva, E. V. Lubennikova, and Inna P. Ganshina

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, First line, first line, Ribociclib, Disease, medicine.disease, cdk4/6 inhibitors, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, Clinical Practice, Breast cancer, breast cancer, Internal medicine, Medicine, ribociclib, business
Abstract

Breast cancer is a leading oncologic disease among women worldwide. Though the achieved results in treating patients with luminal subtypes are high, there is a great demand on new approaches in this field. This article highlights the new CDK4/6 inhibitor ribociclib as well as presents clinical cases from the own clinical practice obtained during phase IIIb COMPLEEMENT trial.

Published
2018

19. Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved?

Author

T E Tikhomirova, L G Zhukova, Inna P. Ganshina, O E Kondratyeva, and E. I. Khatkova

Subjects
Oncology, her2-possitive, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, lcsh:RC254-282, law.invention, Breast cancer, breast cancer, Randomized controlled trial, law, Trastuzumab, Internal medicine, Medicine, skin and connective tissue diseases, Cardiotoxicity, Chemotherapy, business.industry, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Clinical trial, Regimen, trastuzumab, business, Adjuvant, medicine.drug
Abstract

According to the results of the conducted studies in the early 2000’s, adjuvant trastuzumab for 1 year has been admitted the gold standard since 2006. However, the high cost of treatment and the increasing of the risk of cardiotoxicity have led to new clinical trials concerning the short-course trastuzumab regimen. The study deals with the results of the number of the largest randomized trials associated with the comparison of 6 months (the PHARE trial and the HORG study), 9 weeks (the Short-HER study and the SOLD study) and 12 months duration of adjuvant trastuzumab therapy in combination with chemotherapy in patients with HER2-possitive early breast cancer. Today, none of the studies has shown statistically significant evidence of the possibility to reduce the duration of adjuvant trastuzumab therapy.

Published
2018

20. Clinical features and results of surgical treatment of bilateral renal cancer

Author

M. I. Komarov, V. B. Matveev, L. G. Zhukova, I. G. Komarov, and V. A. Chernyaev

Subjects
organ preservation surgery, medicine.medical_specialty, Urology, Disease, Gastroenterology, Renal cell carcinoma, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, synchronous cancer, business.industry, Incidence (epidemiology), bilateral renal cancer, metachronous cancer, Cancer, medicine.disease, Oncology, Nephrology, Concomitant, Clear cell carcinoma, Medicine, Surgery, Metachronous cancer, business, Kidney cancer
Abstract

Renal cancer morbidity grows in most of the developed countries. Incidence of bilateral renal cell carcinoma, per various authors, amounts to 2–6 % of all cases of this disease. The study included 160 patients with bilateral kidney cancer who received surgical treatment at the N.N. Blokhin National Medical Research Center of Oncology in the period from 1996 to 2014. Median follow-up duration for all patients included in the analysis was 81.05 ± 46.7 months. In our study, the groups for synchronous and metachronous cancer were equal (n = 80) and constituted 3.5 % of all cases of kidney cancer. For synchronous and metachronous cancer types, the most common concomitant disease was arterial hypertension. The most common morphological variant for the first, as well as the second, kidney tumor was clear cell carcinoma. Smoking and ischemic heart disease as a concomitant pathology negatively affected relapse-free and overall survival. Overall 5-year survival for synchronous renal cancer was 84.4 ± 4.2 %, for metachronous – 64.8 ± 9.3 %.

Published
2018

21. EXPERIENCE WITH SUBCUTANEOUS TRASTUZUMAB USED IN RUSSIAN FEDERATION

Author

E. V. Lubennikova, I. P. Ganshina, A. N. Lud, D. V. Komov, I. V. Kolyadina, Y. V. Vishnevskaya, I. K. Vorotnikov, D. L. Stroyakovsky, N. A. Savelov, V. F. Semiglazov, А. G. Manikhas, А. V. Osheychik, T. B. Strelnikova, K. R. Zeynalova, and L. G. Zhukova

Subjects
Oncology, medicine.medical_specialty, medicine.medical_treatment, Breast cancer, Trastuzumab, Internal medicine, HER2 Positive Breast Cancer, her2-positive breast cancer, medicine, Effective treatment, In patient, neoadjuvant therapy, skin and connective tissue diseases, Vein, neoplasms, Neoadjuvant therapy, business.industry, General Medicine, medicine.disease, trastuzumab, medicine.anatomical_structure, Tolerability, Medicine, business, medicine.drug
Abstract

The HannaH study showed that neoadjuvante-adjuvant subcutaneous and intravenous trastuzumab have similar efficacy and tolerability in patients with early HER2-positive breast cancer. The analysis of the results of the subcutaneous and intravenous trastuzumab usage in Russian population showed the favorable association between tpCR anf EFS. tpCR achiviement is associated with clinical benefit in HER2 positive breast cancer. For patients with difficult venous access who do not require intravenous chemotherapy currently, Subcutaneous trastuzumab allows to receive effective treatment without the risk of complications, which involves catheterization of a Central vein.

Published
2017

22. Development of cytotoxic chemotherapy in metastatic breast cancer with a triple-negative phenotype

Author

L G Zhukova and Elena Karabina

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, education.field_of_study, business.industry, medicine.medical_treatment, Population, Cytotoxic chemotherapy, medicine.disease, Metastatic breast cancer, Confidence interval, chemistry.chemical_compound, chemistry, Relative risk, Internal medicine, Overall survival, medicine, business, education, Eribulin
Abstract

Treatment of patients with metastatic breast cancer (BC) with a triple-negative phenotype represents the most difficult challenge for clinicians. The optimal chemotherapy regimens for triple-negative BC (TNBC) have not been determined for a long time. However, in the later periods were found molecular agents of application (6 subtypes of TNBC) for the specific therapeutic agent and were performed many studies and subunit analysis, examined appropriate drugs for TNBC. Cell lines of these subtypes have different anticancer drug sensitivity. The results of further studies of targeted drugs using as monotherapy or in combination with chemotherapy in patients with TNBC, in spite of molecular genetic evidence for their application, have fallen short of expectations, although have shown increase in progression-free survival and overall survival. The development of eribulin (nontaxane microtubule dynamics inhibitor) in 2010 significantly increased the possibility of therapy in patients with locally advanced and metastatic BC who had already received chronic treatment. According to the joint analysis of the randomized phase III EMBRACE trial and Study 301, which included data about 1864 patients, it was demonstrated that eribulin statistically significant improve overall survival compared with other drugs using as monotherapy in the general population and among patients with TNBC [statistically significant differences in overall survival was associated with the subgroup of TNBC in patients who had been treated with eribulin, in comparison with the control arm: 12.9 and 8.2 months, respectively (relative risk 0.74; 95% confidence interval, 0.60 to 0.92, p=0.006)]. This article deals with the own experience of successful and long-term eribulin application in young woman with TN metastatic BC who have had already received chronic treatment.

Published
2016

23. Immunological predictive and prognostic factors in patients with stage II-III triple negative breast cancer

Author

Kadagidze Zg, Esma Shoua, Yana V Vishnevskaya, Andrey Meshcheryakov, Zabotina Tn, L G Zhukova, Inna P. Ganshina, Irina V. Kolyadina, Slavina Eg, A. I. Chertkova, and Olga O. Gordeeva

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, chemical and pharmacologic phenomena, hemic and immune systems, Stage ii, medicine.disease, Breast cancer, Internal medicine, medicine, In patient, business, Complete response, Triple-negative breast cancer
Abstract

e12581 Background: Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Pathologic complete response (pCR) achievement during neoadjuvant chemotherapy (NACT) is very important for these pts as it correlates with long-term outcome. Predictive and prognostic factors for this group of pts are needed. Methods: Since 2014 we treated 98 pts with histologically confirmed stage II-III TNBC with following regimen of NACT: 6 cycles of Cisplatin 75mg/m2 day 1 and Paclitaxel 80mg/m2 days 1, 8, 15, every 4 weeks according to local protocol. After NACT pts proceeded to radical breast surgery with assessing of pathological response. Before the treatment we assessed TILs in biopsy samples of all patients. We also conducted subpopulation analysis of lymphocytes in peripheral blood before treatment. We analyzed CD8+, CD25+, NK and NKT cells as they were reported to be significant earlier. We compared results with median value in reference group (mRG) of healthy women. Results: Among all 98 pts 86 (87%) were operated, pCR was achieved in 60,5% of operated pts. pCR strongly correlated with TILs level: 38,5% for pts with TILs < 5% and 69,8% for pts with TILs > 5% (p = 0,05). We also found that NKT population was associated with pCR: 77,8% vs 45,8% among patients with NKT above mRG and up to mRG, respectively (p = 0,01). It correlated also with tpCR: 22,2% vs 70,6% (p = 0,01). When both CD25+ and NKT population were above mRG pCR rate achieved in 85,7% pts vs 50,0% pts if it was up to mRG (p = 0,049). NK, CD8+ and CD25+ did not show any correlation with pCR. Survival results are presented in table below. NK, NKT and TILs did not show any correlation with survival. Interestingly, CD8+ were also associated with lower incidence of visceral metastases: 42,1% in pts with normal CD8+ and 15,7% in pts with CD8+ above normal (p = 0,19). Conclusions: Not only TILs, but also NKT and CD25+/NKT population in the peripheral blood could be possible predictive factors for patients with stage II-III TNBC receiving NACT. CD8+, CD25+ and NKT populations could be further studied as prognostic markers for this group of patients. [Table: see text]

Published
2020

24. Advantages of intraoperative digital specimen radiography (IDSR) in breast surgery

Author

Nikita Maksimov, L G Zhukova, Gurami Kvetenadze, Khalil Arslanov, Anton Smirnov, and Evgeniy Shivilov

Subjects
Cancer Research, medicine.medical_specialty, Breast cancer, Oncology, business.industry, Breast surgery, medicine.medical_treatment, medicine, Radiology, medicine.disease, Specimen radiography, business
Abstract

e12613 Background: Breast cancer is in first place among malignant diseases in women in Russia. We can provide, in most cases, breast-conserving surgery (BCS), due to progress in early diagnosis. Evaluation of positive margins is still one of the most important objectives in breast-conserving surgery. Objectives: To assess the benefits of IDSR in BCS of patients with “carcinoma in situ”. Methods: The results of treatment of 55 patients with breast cancer “carcinoma in situ” in our clinic were evaluated in two comparable groups. Group A included 28 patients, who were operated on from January 2019 to June 2019 and had breast-conserving surgery without IDSR. Group B included 27 patients, who were operated on from June 2019 to January 2020 and had breast-conserving surgery with the evaluation of margins by IDSR. Results: In a planned histological examination positive margins were detected in group A in 4 cases (14%) and required reoperation. In group B all margins were clear. After IDSR, 6 (22%) patients out of 27 in this group showed microcalcifications in the resection margins or at a distance of less than 1 mm and required intraoperative additional excision to obtain clean margins. Conclusions: IDSR reduces the frequency of reoperation due to increased detection of positive margins, allows to correct scope and duration of surgery because of impact on the time of the surgical decision-making process.

Published
2020

25. LYMPHOCYTE SUBSETS IN PERIPHERAL BLOOD OF HER2-POSITIVE AND TRIPLE NEGATIVE BREAST CANCER PATIENTS

Author

V. A. Nurtdinova, I. P. Ganshina, E. G. Slavina, A. I. Chertkova, A. A. Borunova, M. F. Okruzhnova, E. K. Shoua, Z. G. Kadagidze, and L. G. Zhukova

Subjects
Oncology, medicine.medical_specialty, education.field_of_study, medicine.diagnostic_test, business.industry, medicine.drug_class, Population, General Engineering, FOXP3, Monoclonal antibody, Flow cytometry, Immunophenotyping, Internal medicine, medicine, Cancer research, General Earth and Planetary Sciences, Cytotoxic T cell, business, education, Intracellular, Triple-negative breast cancer, General Environmental Science
Abstract

The aim of this study was to investigate the relationship between the original amount of basic lymphocyte subpopulations in peripheral blood and the results of therapy in patients with HER2+ and triple negative breast cancer. Before treatment was conducted immunophenotyping of peripheral blood lymphocytes by flow cytometry using a panel of monoclonal antibodies to surface markers and intracellular lymphocyte antigen FOXP3 and determining the cytotoxic activity of NK-cells. Cytotoxic activity was determined with MTT colorimetric test against K-562 cells. Revealed some differences in the composition of the population of lymphocytes and the number of regulatory T cells in patients with HER2+ and triple negative breast cancer (BC). Discuss the relationship between the number of suppressor cells and the degree of therapeutic pathomorphosis of tumor.

Published
2015

26. HER2 cluster amplification as a factor of an especial sensitivity for anti-HER2 neoadjuvant therapy with biosimilar of trastuzumab in Russian women with breast cancer stage II-III

Author

G A Frank, Irina V. Kolyadina, Irina V. Poddubnaya, Nikita Savelov, Yana V Vishnevskaya, Olga O. Gordeeva, L G Zhukova, Elena Tuzova, L E Zavalishina, Aleksandr V. Arkhipov, Vahan Yurikovich Bokhian, Dmitry Komov, Yulia Andreeva, and Inna P. Ganshina

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Biosimilar, Disease cluster, medicine.disease, Breast cancer, Breast Cancer Stage II, Trastuzumab, Internal medicine, medicine, Stage (cooking), skin and connective tissue diseases, business, Neoadjuvant therapy, medicine.drug
Abstract

e12102 Background: Effect of neoadjuvant chemotherapy (NACT) is extremely important for patients with HER2-positive breast cancer stage II-III as it correlates with long-term outcomes. However, predictive factors for achieving complete pathologic response (pCR) remain unclear. Aim of the study: Assess an impact of clinical, morphological and genetic factors on pCR achievement in patients with HER2-positive breast cancer stage II-III treated by biosimilar of trastuzumab. Methods: We studied treatment results in 73 patients with HER2-positive breast cancer (BC) stage II-III (aged 29-71, median – 51 years), treated with NACT with anti-HER2 therapy and radical surgery in “N.N. Blokhin National Medical Research Center of Oncology” оf the Ministry of Health of the Russian Federation in 2015-2018. After radical surgery pathologic response was assessed. Initially operable tumors were observed in 45,2% patients, locally advanced - in 53,4%. Luminal HER2-positive BC was diagnosed in 41,1%, non-luminal HER2-positive in 58,9%. Ki67 was high (≥ 20%) in 91,5%. NACT included anthracycline and non-antracycline regimens with addition of biosimilar of trastuzumab ± pertuzumab. Radical mastectomy was performed in 78,8% patients, 21,2% had breast-conserving surgery. We studied biopsies obtained before the start of treatment in all women, HER2 amplification was detected by HER2 IQFISH pharmDx (DAKO) kit in accordance with ASCO/CAP 2018 guidelines. In 87,1% HER2+ status was defined as ASCO/CAP 2018 category 1; cluster amplification was detected in 30,1% patients. We analyzed the rate of bpCR и tpCR achievement depending on clinical, pathological data and amplification of HER2. Results: Pathologic complete response in primary tumor (bpCR) was achieved in 57,4%, both in primary tumor and lymph nodes (tpCR) – in 48,9% patients; bpCR achievement depended on age, NACT regimen, addition of pertuzumab and HER2 copy number ( < 0,05). The highest rate of bpCR was noted in women aged 50 and older (71,9%, p = 0,026); in patients received TCH±Р regimen (80,0%, p = 0,045); with addition of pertuzumab (88,9%, p = 0,049); and if cluster amplification was detected (81%, p = 0,013). Cluster amplification was the only one significant predictive factor for achieving tpCR: with cluster amplification - 68,8%, without - 38,7% (p = 0,049). Conclusions: Cluster amplification of HER2 is the most significant factor of especial sensitivity for NACT with biosimilar of trastuzumab in HER2-positive BC stage II-III.

Published
2019

27. Role of clustered amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer

Author

L E Zavalishina, Irina V. Poddubnaya, Inna P. Ganshina, E. A. Tuzova, L G Zhukova, N. A. Savelov, Yu Yu Andreeva, A. A. Meshcheryakov, G A Frank, Irina V. Kolyadina, D. A. Morozov, and Olga O. Gordeeva

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, medicine.disease, Chemotherapy regimen, Primary tumor, Pathology and Forensic Medicine, 03 medical and health sciences, Regimen, 030104 developmental biology, 0302 clinical medicine, Breast cancer, Trastuzumab, 030220 oncology & carcinogenesis, Internal medicine, medicine, Pertuzumab, Radical surgery, business, Radical mastectomy, medicine.drug
Abstract

OBJECTIVE To evaluate the influence of clinical and morphological factors and HER2 copy numbers on pathologic complete response (pCR) rates in patients with HER2-positive stage II-III breast cancer (BC). MATERIAL AND METHODS Treatment results were studied in 73 patients with HER2-positive Stage II-III BC, who received treatment at the N.N. Blokhin National Medical Research Center of Oncology in 2015 to 2018. Treatment included neoadjuvant chemotherapy (NACT) with HER2-blockade and radical surgery followed by the evaluation of a pathologic response in the primary tumor and regional lymph nodes. The patients` age varied from 29 to 71; its median was 51.5; 45.2% of patients had primary operable stages (T1-3N0-1) and 54.8% had locally advanced tumors. All the patients had grade 2-3 anaplasia; luminal HER2-positive BC was diagnosed in 41.4% of patients; hormone-negative tumors were seen in 58.9%; 91.5% of patients had Ki-67 ≥20% in 75.3% of patients, preoperative systemic therapy included anthracycline-containing regimens (4AC + 4 x paclitaxel 175 mg/m2/12 × weekly administrations of paclitaxel 80 mg/m2; trastuzumab therapy was simultaneously performed with the administration of taxanes in the standard regimen) and anthracycline-free regimen TCH ± Pertuzumab regimen in 24.7% of cases. After NACT patients underwent surgery (radical mastectomy in 78.1%, breast-sparing treatment in 21.9%) with the assessment of morphological findings. Biopsy specimens obtained before the treatment was restudied; HER2 amplification was detected using a Dako HER2 IQFISH pharmDx kit according to its instruction and the 2018 ASCO/CAP guidelines. In 87.1% of cases, the HER2-positive status corresponded to the first category of the 2018 ASCO/CAP criteria for HER2-positive BC; clustered HER2 amplification was found in 30.1% of cases. The authors analyzed the frequency of bpCR and tpCR attainment by various clinical and morphological factors, as well as the impact of a HER2 amplification level on pCR rates. RESULTS A breast pCR (bpCR) was achieved in 57.4% patients; bpCR and lymph node CR (lnCR) were noted in 48.9% patients. The rates of bpCR significantly depended on female age, chemotherapy regimen, addition of Pertuzumab, and HER2 copy number. That of bpCR in women less than 35 years of age, in those aged 36-50 years, and in those aged older than 50 years was 22.2, 57.7 and 71.9%, respectively (p=0.026). The maximum bpCR rate observed with the TCH±P regimen was 80.0%, that with anthracycline-containing regimes was 52.8% (p=0.045), and the addition of Pertuzumab increased complete response rates up to 88.9% (that with Trastuzumab was 54.2% (p=0.049). The relationship of bpCR rates to the detection of cluster amplification turned out to be highly significant (81% in its detection and 48.9% in its absence (p=0.013). In addition, clustered HER2 amplification was the only significant predictive factor for complete regression in the primary tumor and lymph nodes: in its presence, the tpCR rate reached 68.8% versus 38.7%. CONCLUSION Clustered amplification of the HER2 gene is the most significant factor of sensitivity to anti-HER2 therapy for Stage II-III BC, and is associated with the maximum rate of both bpCR and total pCR. Further study of this factor may assist in optimizing the treatment algorithm for HER2 + BC.

Published
2019

28. Clinical outcome of Russian HER2-positive breast cancer patients with brain metastases: Retrospective review

Author

L G Zhukova, K. R. Zeynalova, E. Moskvina, A. H. Bekyashev, E. Kobyakova, E. Vetlova, Inna P. Ganshina, and E. Lubennikova

Subjects
Oncology, Cancer Research, Retrospective review, medicine.medical_specialty, business.industry, medicine.disease, Predictive factor, Breast cancer, HER2 Positive Breast Cancer, Internal medicine, Medicine, HER2 Amplification, skin and connective tissue diseases, business
Abstract

e13025Background: HER2 amplification/overexpression is a prognostic and predictive factor for the development of breast cancer (BC) metastases to central nervous system. Anti-HER therapy improve ov...

Published
2018

29. Clinical and biological features and response to preoperative chemotherapy in Russian women with breast cancer stage T1-3N0-1 according to genetic status

Author

Vahan Yurikovich Bokhian, Inna P. Ganshina, Liudmila Lyubchenko, L G Zhukova, Dmitry Komov, Olga Pavlikova, Nikolay Kozlov, Irina V. Poddubnaya, and Irina V. Kolyadina

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Genetic Status, Stage t1, medicine.disease, Breast cancer, Genetic breast cancer, Internal medicine, Medicine, Preoperative chemotherapy, Stage (cooking), business
Abstract

e12651Background: clinical and biological features and response to preoperative chemotherapy in genetic breast cancer (BC) stage T1-3N0-1 are poorly understood. Methods: Our study included 213 wome...

Published
2018

30. The effectiveness, safety and economic rationality of the neoadjuvant chemotherapy with biosimilar of Trastuzumab in HER2+ breast cancer in Russian clinical practice

Author

Olga Pavlikova, Irina V. Kolyadina, Vahan Yurikovich Bokhian, Yana V Vishnevskaya, L G Zhukova, Dmitrii Komov, Inna P. Ganshina, Olga O. Gordeeva, and Irina V. Poddubnaya

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Rationality, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Trastuzumab, Internal medicine, medicine, skin and connective tissue diseases, neoplasms, Chemotherapy, business.industry, virus diseases, Biosimilar, medicine.disease, Clinical Practice, 030104 developmental biology, 030220 oncology & carcinogenesis, business, geographic locations, medicine.drug
Abstract

e12656Background: The biosimilar of trastuzumab (Herticad ®) used in Russian clinical practice since March 2016, but the effectiveness, safety and economic rationality of biosimilar of trastuzumab ...

Published
2018

31. ERCC1 and XRCC1 as prognostic biomarkers for early HER2-positive breast cancer

Author

L G Zhukova, E I Borisova, D. Khochenkov, Inna P. Ganshina, E. Lubennikova, Mikhail Lichinitser, Yana V Vishnevskaya, and E V Stepanova

Subjects
Oncology, Cancer Research, medicine.medical_specialty, DNA repair, business.industry, medicine.disease, XRCC1, Breast cancer, Internal medicine, HER2 Positive Breast Cancer, medicine, ERCC1, business
Abstract

e12562Background: A few prognostic factors are used to make decision on breast cancer (BC) treatment. Researches to identify novel prognostic and predictive factors are still actual. Two DNA repair...

Published
2018

32. [Untitled]

Author

N.V. Zhukov, L. G. Zhukova, and M. R. Lichinitser

Subjects
Oncology, medicine.medical_specialty, Chemotherapy, Poor prognosis, business.industry, medicine.medical_treatment, Locally advanced, Tumor cells, General Medicine, medicine.disease, General Biochemistry, Genetics and Molecular Biology, Vascular endothelial growth factor, chemistry.chemical_compound, Breast cancer, chemistry, Internal medicine, cardiovascular system, medicine, In patient, sense organs, Receptor, business
Abstract

We studied expression of Flt-1 and Flk-1 receptors on tumor cells obtained from 83 patients with locally advanced breast cancer after neoadjuvant chemotherapy. The mean period of observations was 32.3 months. The median recurrence-free survival periods for Flt-1+ and Flt-1- patients were 55 and 32 months, respectively (p=0.0064). The overall survival periods for Flt-1- and Flt-1+ patients were 45 and 67.6 months, respectively (p=0.014). The mean recurrence-free survival periods for Flk-1+ and Flk-1- patients were 40.8 and 60.9 months, respectively (p=0.035). Expression of VEGF had no prognostic value. Our results show that overexpression of Flk-1 on breast cancer cells in patients receiving neoadjuvant chemotherapy is associated with a poor prognosis. By contrast, overexpression of Flt-1 improves survival.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results